header logo image


Page 24«..1020..23242526..3040..»

Archive for the ‘Genetics’ Category

Terrace Global Announces Genetics Supply Agreement With Apollo Green for Acquisition of Genetics and Importation Into the European Union – Business…

Saturday, February 1st, 2020

TORONTO--(BUSINESS WIRE)--Terrace Global Inc. (Terrace Global or the Company) (TSXV:TRCE) is pleased to announce that it has entered into a genetics supply agreement (the Genetics Supply Agreement) with Apollo Green Inc. (Apollo Green) whereby the parties have entered into an exclusive relationship with respect to the acquisition and importation of high-THC genetics for the Companys medical cannabis operations in Portugal.

Terrace Global has commenced the process to acquire the requisite starting materials for the first phase of its greenhouse facilities in Portugal, which will be comprised of approximately 65,000 square feet of greenhouse facilities, a 5,000 square feet of E.U. GMP processing and drying facility and a 3,300 square feet administrative building.

Pursuant to the Genetics Supply Agreement, Terrace Global will be acquiring the following genetics: Chem Stallion (15-25% THC, 0.5-0.1% CBD), Twisted Grape (15-25% THC, 0.5-0.1% CBD) and Apollo Skunk (15-25% THC, 0.5-0.1% CBD). These genetics will add to Terrace Globals existing inventory of high CBD genetics which were acquired from Colorado and used in its outdoor cultivation in Uruguay.

We are pleased to be working with Apollo Green to develop our genetics inventory with a view to focusing on high-THC strains that we expect to be well received by the European Union medical cannabis market participants. Apollo Green has an extensive library of genetics that include a diverse set of market leading strains and cross-breeds, commented Francisco Ortiz von Bismarck, Chief Executive Officer of the Company. Being able to source these genetics is an important milestone in the development of European operations. Without quality genetics, there is no pathway to success in the burgeoning E.U. medical cannabis industry.

Apollo Green has been accumulating an extensive library of high-THC genetics and has benefited from its relationship with Ed Rosenthal. Mr. Rosenthal is a Global Advisor to Apollo Green and is a leading cannabis horticulture authority, author, educator, social activist and legalization pioneer.

Terrace Global is building a world-class cultivation facility in one of the most attractive countries from a regulatory and climate perspective. We will be working closely with the Company to see how these genetics perform by leveraging our extensive cultivation expertise, commented Tyler LeBlanc, Chief Executive Officer of Apollo Green. This is a meaningful partnership for us as we seek to grow our genetics and plantlet business globally. Terrace Global is the ideal partner given its extensive experience and international footprint in Uruguay, Portugal and Spain.

The Genetics Supply Agreement is subject to various conditions precedent, including the issuance of the applicable export and import permits from the regulatory authorities in Canada and Portugal.

About Terrace Global

Terrace Global is a multi-country operator (MCO) led by experienced cannabis entrepreneurs focused on the development and acquisition of international cannabis assets. Terrace Globals focus is on federally legal jurisdictions with existing domestic demand, low cost inputs and approved for exportation. Terrace Globals existing asset platform consists of: (1) a 33.75% indirect equity interest in one of the currently two recreational cannabis operations in Uruguay; (2) 100% of Oransur, S.A., a Uruguayan company producing high CBD hemp in Uruguay; (3) 100% of Terra Nova Produo e Comercializao de Produtos Natuis e Farmacuticos, Lda, a Portuguese company with a pre-license issued by INFARMED for the cultivation, importation, and exportation of medical cannabis in Portugal; and (4) 100% of Pharmabinoide S.L., a Spanish company producing and commercializing hemp in Spain. MariMed Inc. (OTCQX:MRMD), a multi-state cannabis operator in the U.S., dedicated to improving the health and wellness of people through the use of cannabinoids and cannabis products, owns approximately 6% of Terrace Global.

About Apollo Green

Apollo Green was among the first wave of Canadian businesses to submit an application to Health Canada for a cannabis cultivation and sales license. In July 2019, Apollo Green was granted three licenses for standard cultivation, standard processing and federal medical sales. Apollo Green currently supplies premium genetic solutions and superior plantlets to Cannabis producers globally, specializing in reducing risk, space, costs, and time to its B2B customers, in a state of the art fully operational facility about 20 minutes east of downtown Ottawa.

FORWARD-LOOKING STATEMENTS

This news release contains certain forward-looking statements, including, but not limited to, statements about the Companys future plans and intentions. Wherever possible, words such as may, will, should, could, expect, plan, intend, anticipate, believe, estimate, predict or potential or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect managements current beliefs and are based on information currently available to management as at the date hereof.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Read more:
Terrace Global Announces Genetics Supply Agreement With Apollo Green for Acquisition of Genetics and Importation Into the European Union - Business...

Read More...

Genetics research at BYU may not be what you think – Universe.byu.edu

Saturday, February 1st, 2020

See also BYU researchers contribute toward finding a cure for Alzheimers disease

Genetics and Alzheimers researchers at BYU have made far-reaching contributions to their fields through two valuable campus resources: the DNA Sequencing Center (DNASC) and the Office of Research Computing.

These resources generate data that is used by BYU faculty researchers, students and collaborators from other universities in their research.

Although many people approach the DNASC requesting sequencing for family history and genealogy related samples, these services are currently not offered. The DNASC, along with the Office of Research Computing, is centered on the primary focus of providing support for academic research.

DNA Sequencing Center

Inside the Life Sciences Building is a collection of small rooms that make up what is known as the BYU DNASC. This center is vital to researchers and houses DNA sequencing machines that are dedicated to efficiently and economically processing DNA samples.

Edward Wilcox, managing director of the sequencing center, has worked as a full-time research faculty member since 2005. He manages everything from the DNA sequencing machines to student employees who help prepare samples.

The process of preparing DNA samples involves isolating them, shearing them down to the right size, making libraries and cleaning them.

A library is just pieces of DNA with adapters on the ends, Wilcox said. The adapters are what allows us to sequence in since its a known sequence. From there, we can sequence into the unknown.

After the libraries are prepared, they are ready to be placed in the sequencing machines. The DNASC currently has three machines: the Illumina, PacBio I and PacBio II. The 2015 Illumina will retire at some point and be replaced by a new machine called the NovaSeq. This machine will cost about a million dollars but is essential for the work and is expected to generate more data at less of a cost.

Handling all this expensive equipment requires great care. Wilcox admits he may come off as overbearing to student employees at times, but thats because everything needs to be done just right.

Thats $20,000 of reagent (a substance or compound added to a system to cause a chemical reaction) were putting on the machines right now. If we dont do things right, and the run fails, were out $20,000, Wilcox said. Its a little concerning, and we cannot afford to lose a run.

BYU junior Miranda Johnson has been working at the DNASC since September 2018. The neuroscience major said the job is stressful and requires a lot of multitasking.

But its less stressful than customer service in my opinion, Johnson said.

The DNASC receives a variety of different samples from all across the United States and the world, including recent samples from Russia, the Czech Republic and Italy. The samples can come from any living organism, including fish, plants, insects, sunflowers and blood.

Its pretty random what we get, Johnson said. Thats the fun part of the DNA Sequencing lab! Its familiar enough you dont get lost, but its always a little bit different.

BYU biology professor and Alzheimers researcher John Kauwe said the DNASC is an important resource that nearly everyone doing genetics research at BYU relies on for some aspects of their data generation.

Its great to have that resource right down the hall, where we know we can get high-quality data, Kauwe said.

The Office of Research Computing

The Office of Research Computing is another vital resource for research at BYU. With over a thousand computer servers and 24,000 processor cores, this valuable resource is utilized by hundreds of users, including BYU faculty researchers, students and a few dozen collaborators from other universities.

Nothing I do would be possible without it, said Perry Ridge, an Alzheimers researcher and biology professor at BYU. Every analysis that we run for every project is on the supercomputer.

Research director computing Ryan Cox oversees the entire office, running everything from the servers to the employees. His team does everything from maintaining the hardware and software that researchers use and purchasing new equipment to staying on top of industry trends and helping people with code optimizations.

The servers that make up the supercomputer are located in three separate rooms across the BYU campus, the biggest being in the James E. Talmage Building. Several departments on campus rely on this resource especially the engineering, physical, mathematical and life sciences colleges.

The DNASC in the life sciences college sends terabyte-sized files to the servers on a weekly basis. Wilcox, the managing director of the sequencing center, said not having enough computer space has been one of their biggest challenges.

Were dealing with some big files here, Wilcox said. The computer center at BYU limits you to 15 terabytes; thats a weeks worth of data and its hard to distribute everyones data in that time.

Realizing this was an issue, Cox said the Office of Research Computing recently started renting out storage space to accommodate those who need the extra space.

Some people use 80 to a 100 times more storage than the allocation we give people, Cox said.

Generally the research computing sources are freely available to everyone, but the limited storage space makes it difficult to satisfy everyones needs. But according to Ridge, Cox and his team are always finding ways to accommodate those in the research community.

The Office of Research Computing is service-oriented and they go out of their way to help faculty and students in doing research, Ridge said. They really make a lot of what we do here at BYU possible, and make it possible for BYU to stand out in positive ways.

Kauwe agrees and added that these campus resources help him and his colleagues make a positive impact in their fields of research.

Its been wonderful coming here and having a DNA sequencing center and a high quality research computing center to analyze the scale of data were generating, Kauwe said. Its allowed us to be competitive on a national scale and to make research progress that is meaningful in our field. They are incredible resources that are key to genetics research at BYU.

See the article here:
Genetics research at BYU may not be what you think - Universe.byu.edu

Read More...

How Genetic Testing with 23andMe Can Improve Your Health – Yahoo Finance

Saturday, February 1st, 2020

Survey finds 23andMe Health + Ancestry results motivate customers to make positive lifestyle changes.

NEW YORK, Jan. 30, 2020 /PRNewswire-PRWeb/ -- At-home DNA testing service 23andMe is more than just a tool to discover ancestry - it also offers insight into how genes can impact overall health and wellness. 23andMe offers a wealth of reports that provide genetic health information that can help customers be more proactive about their health. Recently, 23andMe Genetics Trends Expert, Madeline Lynch, and customer Michelle Martinez, teamed with YourUpdateTV to discuss.

A video accompanying this announcement is available at: https://youtu.be/VAKAywAd4VY

A recent survey of 23andMe's Health + Ancestry Service customers found that more than three-quarters reported that after receiving their personalized genetic reports they made at least one positive change in their health behavior. Designed by 23andMe and M/A/R/C Research, researchers asked 23andMe Health + Ancestry customers about the overall impact of their 23andMe experience, regardless of their results.

51 percent of respondents reporting they've set future goals to be healthier. Changes included eating healthier, getting more sleep, and exercising more, among others. Of those who responded to the survey:

For more information and to get started, visit 23andMe.com

Madeline Lynch: Madeline Lynch is the Genetics Trends Expert at 23andMe. She serves as a subject matter expert and company spokesperson for media engagements, the analyst community, online communities, and the general public at large. Her responsibilities on the customer care team include providing input on prioritization and resolution of customer-facing issues and working directly with cross-functional teams to influence and support development of new and existing communications materials and messaging from the perspective of the customer. She holds a BA from University of California, Davis.

About Michelle Martinez: Michelle Martinez is a 51-year-old lab assistant from Arlington, Texas. Michelle was inspired to order a 23andMe Health + Ancestry kit to help prepare for any potential genetic health risks, due to several serious health risks running in her family. When she opened her Genetic Weight wellness report, she saw that she is genetically predisposed to weigh less than average. She thought, "I've been denying my genetics and just falling into bad habits. I'm not being my best self." That report, along with the knowledge of lifestyle and environmental factors that affect one's health, inspired Michelle to make better lifestyle decisions like eating healthier. She has since lost more than 50 pounds and gained confidence in being in her own skin. She believes that her weight loss journey is one of patience and acceptance with and of herself -- no matter her size.

About 23andMe: 23andMe, Inc. is the leading consumer genetics and research company. Founded in 2006, the mission of the company is to help people access, understand and benefit from the human genome. The company was named by TIME as a "Genius Company" in 2018 and featured as Fast Company's #2 Most Innovative Health Company in 2018. 23andMe has millions of customers worldwide, with more than 80 percent of customers consented to participate in research. 23andMe, Inc. is located in Sunnyvale, CA. More information is available at http://www.23andMe.com.

About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content, produced by award-winning video communications firm, D S Simon Media (http://www.dssimon.com). It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology.

SOURCE 23andMe

Follow this link:
How Genetic Testing with 23andMe Can Improve Your Health - Yahoo Finance

Read More...

Genetic risk scores open a host of concerns and implications – The Daily Cardinal

Saturday, February 1st, 2020

A world where we can predict what traits and diseases that a baby will be born with is nearly upon us. With the expanding availability of genetic data, researchers in both universities and industry are trying to figure out the complicated relationship between our DNA and human health. For traits and diseases that reflect the interaction between many genetic and oftentimes environmental risk factors, these sorts of predictions are more difficult to make.

Scientists use genome-wide association studies with very large sample sizes to calculate polygenic scores, which correlate genetic factors with complex traits, like height or BMI, and risk for complex diseases, like heart disease or autism.

Almost everything you can think of is highly polygenic meaning [that] many, many, many genes or hundreds of thousands of genetic locations could be affecting [a complex trait], Jason Fletcher, a UW-Madison professor of public affairs studying some of the ethical, legal and social implications of genomic science, said.

Since an individuals genome generally does not change over the course of their lifetime, polygenic scores could offer an avenue for identifying individuals for specialized treatments or early interventions, Fletcher adds.

The positive case might be something like thinking about an instance where there is polygenic score for dyslexia and potentially being able to use a score like that very early in a child's life as a way of collecting individuals who might benefit from specific learning interventions, Fletcher said.

Intellectual disabilities and learning disabilities often go unnoticed for years, which can leave a child to struggle.

Lauren Schmitz, a UW-Madison assistant professor of public affairs, also notes that whereas for heart disease, preventative measures are viewed favorably, for intellectual disability the measures used to intervene would need to be carefully considered to avoid stigmatizing individuals.

Schmitz also stresses that although the science is moving fast, the predictive accuracy of these polygenic risk scores varies depending on the trait or disease in question. However, the for-profit, direct-to-consumer DNA testing industry is blurring the lines on what genomic science can say.

The way I see it, it's the next frontier in personalized things, Schmitz said. I think we're a culture that loves things that are personalized to us me and my experience and so I think the genome is the next marketing frontier.

For example, last November the biotech company Genomic Prediction claimed it could offer polygenic scores for traits including diabetes, heart disease and even IQ as an additional amenity for parents having children through in vitro fertilization. Currently, IVF clinics test fertilized embryos before they are implanted into a uterus to check for inherited genetic disease, like cystic fibrosis or Tays-Sachs disease, or for major chromosome abnormalities that can dramatically decrease the likelihood of a fetus being carried to term.

The announcement has been met with concern from scientists about the accuracy of these new preimplantation tests as well as the long-term effects of selecting on the basis of these traits.

There's all sorts of things where we don't even understand how these different mechanisms are operating and how they're correlated with other aspects of the genome, Schmitz said.

Measurements of intelligence like IQ tests are controversial, and as Angela Saini writes in Superior: The Return of Race Science, much of the work correlating educational attainment with genetics has direct ties to the vestiges of the eugenics movement in the early 20th century. Additionally, for many complex traits and diseases in combination with social and environmental factors at play, these polygenic scores are not necessarily an indication that the trait or disease will manifest.

We should be clear that the scores are not destiny, and there's an upper limit on how predictive it could be, Fletcher said.

Original post:
Genetic risk scores open a host of concerns and implications - The Daily Cardinal

Read More...

A Woman Who Accused Trump Of Rape Is Now Seeking His DNA To Test Against Genetic Material Found On Her Dress – BuzzFeed News

Saturday, February 1st, 2020

Lawyers for E. Jean Carroll, who said Donald Trump raped her in a New York department store in the 1990s, are seeking a sample of the president's DNA to determine whether it matches genetic material found on the dress she wore during the alleged assault.

On Thursday, her attorney, Roberta Kaplan, filed court documents calling on Trump to submit a sample on March 2 in Washington, DC, for "analysis and comparison against unidentified male DNA present on the dress" Carroll wore that day.

A Jan. 8 laboratory report attached to the notice said that DNA recovered from the right sleeve of the dress was a mixture of four individuals, Carroll and three others, including at least one male. The report said a number of individuals whose names were redacted were eliminated as potential contributors to the mixture.

This case turns on whether Donald Trump lied when he said that he had not sexually assaulted E Jean Carroll and, in fact, had never even met her," Kaplan said in a statement. "As a result, weve requested a simple saliva sample from Mr. Trump to test his DNA, and there really is no valid basis for him to object.

The lawyer representing Trump in the case did not immediately respond to BuzzFeed News' request for comment.

Carroll, a writer and advice columnist, filed a defamation lawsuit against Trump in November, saying he lied when he denied her rape allegations.

In June, Carroll released a new book, an excerpt from which was published in New York magazine. She alleged Trump raped her in a Bergdorf Goodman dressing room about 23 years ago.

In the dressing room, Carroll alleged Trump grabbed her arms, pinned her against the wall, pulled down her tights, and "thrust his penis" inside her, according to court documents.

After Carroll came forward, Trump denied the allegation and claimed he had "never met that person in my life." He also accused her of making up other allegations Carroll had also accused disgraced former CBS CEO Les Moonves of sexually assaulting her and said the Democratic party must have been involved.

In a statement Thursday, Carroll said that after Trump allegedly sexually assaulted her, she took the black dress she had been wearing and hung it in her closet where it stayed until last year when she wore it for the New York magazine photo shoot.

DNA does degrade over time but, if preserved well, can last millions of years. Genetic material has been obtained from evidence in decades-old cases to use for testing. In 2013, investigators linked the man they believed to be the Boston Strangler, who murdered 13 women in the 1960s, to old fluid samples taken from one victim's body and a blanket from the crime scene.

Unidentified male DNA on the dress could prove that Donald Trump not only knows who I am, but also that he violently assaulted me in a dressing room at Bergdorf Goodman and then defamed me by lying about it and impugning my character," Carroll said.

See the original post here:
A Woman Who Accused Trump Of Rape Is Now Seeking His DNA To Test Against Genetic Material Found On Her Dress - BuzzFeed News

Read More...

OPINION: Jewish or not, this week could save you a lot of heartache – Atlanta Journal Constitution

Saturday, February 1st, 2020

Monday marks the beginning of the first Jewish Genetic Screening Awareness Week.

And, this being February, there are at least a dozen other awareness efforts just as there were in January and will be come March and the nine months that follow. February is, of course, the month in which we raise awareness about HIV/AIDS, Teen Dating Violence and screen for eating disorders, among a long list of other things.

Now comes Feb. 3-7, the week JScreen hopes will get us to focus on genetic screening and more specifically the need for people here and across the country to take charge of their health and any children they hope to have in the future. To kick things off, the Georgia Legislature is expected to pass a proclamation to highlight the effort midweek.

JScreen, you might recall, is a national nonprofit public health initiative dedicated to preventing Jewish genetic diseases. But the goal is to prevent diseases common in other ethnic groups as well, said Karen Arnovitz Grinzaid, an assistant professor of human genetics at Emory University and JScreens executive director.

The nonprofit, based at Emory University, began in 2010 as a pilot project in Atlanta and has since evolved into a national initiative offering affordable, accessible and comprehensive genetic screening.

RELATED |DeKalb couples personal tragedy becomes crusade for genetic testing

Since its national launch in 2013, Grinzaid said, JScreen has helped thousands, testing people from every state across the country and offering services remotely.

That means once you register for a genetic screen kit atjscreen.org, JScreen will mail the kit to your home. All you have to do is spit in a tube and mail the saliva sample to the lab. A genetic counselor will then report the results either by phone or secure video conference.

For people with health insurance, the cost, regardless of coverage, is $149 and includes the testing and follow-up genetic counseling. The self-pay price is $349.

While the focus is on the Jewish community, screening is encouraged for anyone planning to have a family, Grinzaid said.

JScreen screens for over 200 diseases. For most of these diseases, both parents must carry the same recessive gene in order for their children to be at risk.

So why an awareness week?

Were always trying to raise awareness, but by dedicating a week and calling this out, we can save lives, Grinzaid said. So many people dont hear about genetic screening until they show up pregnant in their doctors office. At that point, if they are a high-risk couple, they dont have as many options to help them plan ahead for a healthy baby. Genetic screening is something people should ideally do before they get pregnant.

Unlike other awareness campaigns, JScreens promises to be very purposeful, focusing each day on a specific theme in hopes that more people will take advantage of screening.

RELATED |A mother and her daughters bare all to help prevent breast cancer

On Monday, organizers will be laser focused on Tay-Sachs, a rare, inherited disorder that destroys nerve cells in the brain and spinal cord.

On Tuesday, theyll turn their focus to college students. While having a baby may be the farthest thing from any students mind, discounted screenings will be provided at colleges and universities across the country so students will have access to important information they need for future family planning.

BRCA awareness will follow on Wednesday. Ashkenazi Jews are at 10 times greater risk to have a mutation in a BRCA gene, increasing their risk for breast, ovarian, prostate and pancreatic cancer.

Then on Thursday, Jews with Sephardi and Mizrahi ancestry, such as Persians, Syrians and Bukharians, are encouraged to be screened.

Finally on Friday, interfaith couples will be the focus. While there are a number of diseases that are commonly found in people with Jewish background, Grinzaid said these diseases also occur in the general population, making screening important for interfaith couples as well.

Thats not all.

Beyond carrier screening, Grinzaid said that JScreen is running the PEACH BRCA study for people with Jewish background who are at risk for carrying a BRCA mutation based on their ancestry. Knowing ones BRCA status can be life-saving.

Were piloting BRCA testing in metro Atlanta, she said. Participation in the study is free, but you must be at least 25 or older, male or female, and have at least one Jewish grandparent and no personal or close family history of related cancers.

Of the 500 available slots, only 100 are left. People interested in learning more about the PEACH BRCA study can log on here:jscreen.org/brca.

Once the study is complete, JScreen will launch a cancer genetic testing program nationally.

For information about any of these programs or to register for a screening kit,log onto jscreen.org.

Sure, the focus for now is on this week, but you can get screened any time and you should. Genetic testing is just that important.

Find Gracie on Facebook (www.facebook.com/graciestaplesajc/) and Twitter (@GStaples_AJC) or email her at gstaples@ajc.com.

Support real journalism. Support local journalism. Subscribe to The Atlanta Journal-Constitution today. See offers.

Your subscription to the Atlanta Journal-Constitution funds in-depth reporting and investigations that keep you informed. Thank you for supporting real journalism.

Read the original post:
OPINION: Jewish or not, this week could save you a lot of heartache - Atlanta Journal Constitution

Read More...

My ‘Tiredness’ Turned Out to Be a Genetic Condition That Raises Cancer Risk – msnNOW

Saturday, February 1st, 2020

Courtesy Jen B.

In 2012, Bev Michel found a large lump in her breast. This discovery started a medical odyssey that led to a cancer diagnosis and ultimately unraveled the mystery of a variety of health issues that had plagued her for more than eight years.

Following up on the lump with a mammogram and biopsy, Michel got the startling news that she had cancer. The West Chester, Pennsylvania resident immediately jumped into a chemotherapy regimen, undergoing six sessions of chemo and two lumpectomiesonly to find later after genetic testing that her type of cancer, lobular breast cancer, doesn't respond to chemotherapy. She then requested and underwent a double mastectomy, hoping to ensure the cancer was gone for good. But the cancer recurred in 2016near the nodes. So she again had surgery, this time to remove lymph nodes that she later learned were benign.

Michel felt there had to be more to her troubles, and she went to her general practitioner for guidance. "I told her how I was always tired, and how much my joints ached," Michel recalls. "She ran a couple of blood tests, and when she received the results she didn't believe them. She said my iron levels were sky-high, so she retested them. They were even higher." Michel's doctor diagnosed her with hemochromatosis, a metabolic disorder that leads to abnormally high iron levels in the body.

The mineral deposits itself into organs like the heart, liver, and pancreas, and in the joints; it can raise the risk of cancer and other diseases. A normal human absorbs about 8 to 10 percent of the iron they get from their diet; people with hemochromatosis absorb four times as much. The condition is inherited, and people with northern European ancestry have an elevated risk, according to the Genetics Home Reference. Experts estimate that 16 million Americans have elevated iron levels. Michel's diagnosis helped shed light on her family's medical history. "My mom died of breast cancer, had macular degeneration, and heart issueswhich are all signs of the disorder. When I had genetic testing, my results showed that both of my parents had the gene mutation, so of course, I would, too." (Here, doctors reveal the rarest conditions they've ever diagnosed.)

About one in 227 of people of Northern European descent have the condition, and about 10% of white people in the U.S. are carriers, according to National Organization for Rare Disorders. That means they have one copy of the gene mutation that causes hemochromatosis. You need to inherit two copies of the gene, one from each parent, to have the condition, although not everyone with both genes develops it. It's most often diagnosed in men after age 40 and in women after 60, in the postmenopausal years. While it's one of the most common genetic diseases in the U.S., it's less common in African Americans, and people who are of Hispanic, Asian, or Native American descent.

Michel was told she would need to donate blood every few weeks for the rest of her life, as giving blood regularly helps reduce iron levels. The prospect of this sent her to the internet to research other possible treatments. "What I found was that high iron is correlated to cancer, and I'm convinced it's what caused cancer for both my mom and me," she says."I found a doctor at the University of Maryland, Abulkalam M. Shamsuddin, MB, BS, PhD, who had studied the use of something called IP6 for treatment of cancer and iron overload." IP6 stands for inositol hexaphosphate: It's basically a carbohydrate substance that behaves like a vitamin, and it binds with extra iron in the body, explains Michael. "Once I began taking it, I haven't had a blood draw in two years, and my cancer has not recurred. My doctors are amazed."

Through her journey, Michel has found a passion for educating others about this relatively common yet underdiagnosed disorder. "I think there needs to be more open-mindedness among the medical community regarding treatments for conditions like this. Instead of treating only symptoms, look for the cause," she says.

If you have suspicious symptoms and you're not finding answers, Michel advises you be direct: "Ask to be tested for hemochromatosis. It's not an expensive test. If you have cancer, look for a possible correlation to your iron levels. If you test positive, then consider genetic testing for your children's sake. If you have it, they might, too."

Don't miss the 50 everyday habits that reduce your risk of breast cancer.

Gallery: 50 everyday habits that can reduce your risk of breast cancer

See the original post here:
My 'Tiredness' Turned Out to Be a Genetic Condition That Raises Cancer Risk - msnNOW

Read More...

EMA Validates Seattle Genetics’ Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive…

Saturday, February 1st, 2020

Today, we achieved a significant milestone towards our goal of making tucatinib available to patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, around the world, said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. We look forward to working with the EMA throughout the review process. If approved, tucatinib has the potential to be a clinically meaningful advance for patients in this disease setting.

The MAA is based on data from the pivotal HER2CLIMB clinical trial, which compared tucatinib in combination with trastuzumab and capecitabine to trastuzumab and capecitabine alone in patients with locally advanced unresectable or metastatic HER2-positive breast cancer. Patients had previously received trastuzumab, pertuzumab and T-DM1 (ado-trastuzumab emtansine). Patients had received a median of four prior lines of therapy overall and three in the metastatic setting. Forty-seven percent of the patients enrolled in the trial had brain metastases at the time of enrollment. Results of the pivotal HER2CLIMB trial were presented during an oral presentation at the 2019 San Antonio Breast Cancer Symposium (SABCS) and simultaneously published in the New England Journal of Medicine (NEJM).

The New Drug Application (NDA) for tucatinib was submitted to the U.S. Food and Drug Administration (FDA) on December 23, 2019 under the Real-Time Oncology Review Pilot Program. The review of the tucatinib NDA is also being conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence. Project Orbis provides a framework for concurrent submission and review of oncology drugs among participating international partners. Tucatinib was recently granted Breakthrough Therapy designation by the FDA in combination with trastuzumab and capecitabine, for the treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have been treated with trastuzumab, pertuzumab, and T-DM1. This designation was based on data from the HER2CLIMB trial.

About HER2CLIMB

HER2CLIMB is a multinational randomized (2:1), double-blind, placebo-controlled, active comparator, pivotal clinical trial comparing tucatinib in combination with trastuzumab and capecitabine compared with trastuzumab and capecitabine alone in patients with locally advanced unresectable or metastatic HER2-positive breast cancer who were previously treated with trastuzumab, pertuzumab and T-DM1. The primary endpoint of the trial was progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determined by blinded independent central review (BICR) in the first 480 patients enrolled in the trial. HER2CLIMB enrolled a total of 612 patients to support the analyses of key secondary endpoints, including overall survival, PFS per BICR in patients with brain metastases at baseline and confirmed objective response rate (ORR). Safety data were evaluated throughout the study.

About HER2-Positive Breast Cancer

Patients with HER2-positive breast cancer have tumors with high levels of a protein called human epidermal growth factor receptor 2 (HER2), which promotes the aggressive spread of cancer cells. An estimated 271,270 new cases of invasive breast cancer will be diagnosed in the U.S. in 2019.1 Between 15 and 20 percent of breast cancer cases worldwide are HER2-positive.2 Historically, HER2-positive breast cancer tends to be more aggressive and more likely to recur than HER2-negative breast cancer.2, 3, 4 In patients with metastatic breast cancer, the most common site of first metastasis is in bone, followed by lung, brain, and liver.5, 6 Up to 50 percent of metastatic HER2-positive breast cancer patients develop brain metastases over time.2, 7 Despite recent treatment advances, there is still a significant need for new therapies that can impact metastatic disease, especially brain metastases. There are currently no approved therapies demonstrating progression-free survival or overall survival benefit for the treatment of patients with HER2-positive metastatic breast cancer after progression on T-DM1.8, 9, 10

About Tucatinib

Tucatinib is an investigational, orally bioavailable, potent tyrosine kinase inhibitor that is highly selective for HER2 without significant inhibition of EGFR. Inhibition of EGFR has been associated with significant toxicities, including skin rash and diarrhea. Tucatinib has shown activity as a single agent and in combination with both chemotherapy and other HER2 targeted agents such as trastuzumab.1,2 Studies of tucatinib in these combinations have shown activity both systemically and in brain metastases. HER2 is a growth factor receptor that is overexpressed in multiple cancers, including breast, colorectal and gastric cancers. HER2 mediates cell growth, differentiation and survival. Tucatinib has been granted orphan drug designation by the FDA for the treatment of breast cancer patients with brain metastases.

In addition to HER2CLIMB, tucatinib is being evaluated in a randomized, double-blind, placebo-controlled, multi-center phase 3 trial of tucatinib in combination with T-DM1 compared to T-DM1 alone, in patients with unresectable locally advanced or metastatic HER2-positive breast cancer, including those with brain metastases, who have had prior treatment with a taxane and trastuzumab. The primary endpoint is PFS per RECIST criteria. Secondary endpoints include overall survival, objective response rate and duration of response. This global trial is expected to enroll approximately 460 patients. More information about the phase 3 trial, including enrolling centers, is available at http://www.clinicaltrials.gov.

Tucatinib is also being evaluated in a multi-center, open-label, single-arm phase 2 clinical trial known as MOUNTAINEER, which is evaluating tucatinib in combination with trastuzumab in patients with HER2-positive, RAS wildtype metastatic or unresectable colorectal cancer. The primary endpoint of the trial is ORR by RECIST criteria. PFS, duration of response, overall survival and safety and tolerability of the combination regimen are secondary objectives. Results for 26 patients were evaluated in an analysis and presented at the European Society for Medical Oncology (ESMO) 2019 Congress. Enrollment is ongoing. More information about the MOUNTAINEER trial, including enrolling centers, is available at http://www.clinicaltrials.gov.

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative medicines targeting cancer to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) and PADCEVTM (enfortumab vedotin-ejfv) use the companys industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. In addition, investigational agent tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer, and in clinical development for metastatic colorectal cancer. The company is headquartered in Bothell, Washington, and has offices in California, Switzerland and the European Union. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential of tucatinib, including its possible efficacy, safety and therapeutic uses; anticipated development activities including ongoing and future clinical trials; and the potential to obtain regulatory approvals of tucatinib in the United States, the European Union and in countries participating in Project Orbis. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the difficulty and uncertainty of pharmaceutical product development, the risk of adverse events or safety signals, the possibility of disappointing results in ongoing or future clinical trials despite earlier promising clinical results, the possibility that data from the HER2CLIMB trial may not be sufficient to support approval of tucatinib in the United States, the European Union or in other countries participating in Project Orbis or that other adverse regulatory actions could occur. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption Risk Factors included in the companys Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

References:

1. American Cancer Society, Cancer Facts and Figures 2018-2019.

2. Loibl S, Gianni L (2017). HER2-positive breast cancer. The Lancet 389(10087): 2415-29.

3. Slamon D, Clark G, Wong S, et al. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785): 177-82.

4. American Cancer Society (ACS) (2018). Breast cancer HER2 status. Accessed: December 10, 2018.

5. Kennecke H, Yerushalmi R, Woods R, et al. (2010). Metastatic Behavior of Breast Cancer Subtypes. Journal of Clinical Oncology 28(20): 3271-7.

6. Berman AT, Thukral AD, Hwang W-T, et al. (2013). Incidence and Patterns of Distant Metastases for Patients With Early-Stage Breast Cancer After Breast Conservation Treatment. Clinical Breast Cancer 13(2): 88-94.

7. Duchnowska R, Loibl S, Jassem J (2018). Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer. Cancer Treatment Reviews 67: 71-7.

8. Verma S, Miles D, Gianni L, et al. (2012). Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine 367(19): 1783-91.

9. Geyer CE, Forster J, Lindquist D, et al. (2006). Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine 355(26): 2733-43.

10. Blackwell KL, Burstein HJ, Storniolo AM, et al. (2012). Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study. Journal of Clinical Oncology 30(21): 2585-92.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200131005084/en/

Read more from the original source:
EMA Validates Seattle Genetics' Marketing Authorization Application for Tucatinib for Patients with Locally Advanced or Metastatic HER2-Positive...

Read More...

How one woman became the exception to her familys Alzheimers history – Science News

Saturday, February 1st, 2020

A cruel twist of genetic fate brought Alzheimers disease to a sprawling Colombian family. But thanks to a second twist, one member of the clan, a woman, managed to evade the symptoms for decades. Her escape may hold the key to halting, or even preventing, Alzheimers.

The inherited version of Alzheimers disease erodes peoples memories early, starting around age 40. In this family and others, a mutation in a gene called presenilin 1 eventually leaves its carriers profoundly confused and unable to care for themselves. Locals around the Colombian city of Medelln have a name for the condition: la bobera, or the foolishness.

The woman in the afflicted family who somehow fended off the disease carried the same mutation that usually guarantees dementia. And her brain was filled with plaques formed by a sticky protein called amyloid. Many scientists view that accumulation as one of the earliest signs of the disease. Yet she stayed sharp until her 70s.

Researchers were stumped, until they discovered that the woman also carried another, extremely rare genetic mutation that seemed to be protecting her from the effects of the first one. This second mutation, in a different Alzheimers-related gene called APOE, seemed to slow the disease down by decades, says Joseph Arboleda-Velasquez, a cell biologist at Harvard Medical School.

Headlines and summaries of the latest Science News articles, delivered to your inbox

There was this idea of inevitability, he says. But the womans circumstances bring a different perspective one in which amyloid buildup no longer guarantees problems. Arboleda-Velasquez and colleagues reported the details of the womans exceptional case November 4 in Nature Medicine, omitting the womans name and precise age to protect her privacy.

Although the discovery is based on one person, it points to a biological weak spot in the degenerative disease that affects an estimated 5.8 million people in the United States alone. So far, nearly every clinical trial designed to slow or stop the disease has failed. Those heartbreaking disappointments have prompted scientists to expand their search for treatments.

Perhaps this unusually resilient woman in Colombia shows a way to halt the disease, or at least slow it down. Can we come up with a drug that does this to people who dont have a mutation? asks Arboleda-Velasquez. The potential for that is tremendous.

The vast majority of people with Alzheimers have a sporadic form of the disease with no clear genetic culprit. These people often reach their 70s or 80s before signs of dementia appear. Mutations that cause trouble much earlier, such as the Paisa mutation found in the Colombian family, are unusual. But despite their different origins and different timelines, these two versions of Alzheimers are thought to progress in somewhat similar ways.

Normally, presenilin 1 makes a protein that helps chop up the long, sticky amyloid precursor protein. One of the resulting small bits is called amyloid-beta. Those smaller pieces are harmlessly washed out of the brain. The mutated presenilin 1 gene found in the Colombian family, however, creates a kink in the chopping process that leads to an abundance of a version of amyloid that knits itself into plaques between brain cells.

This pileup is already visible in brain scans of people in their 20s who carry the mutation. By their mid-40s, many of these people have trouble remembering; they typically develop full-blown dementia by age 50.

Inheriting just one copy of the mutation is enough to lead to excess amyloid, and ultimately dementia. The mutations powerful effect in this family is one of the strongest arguments for the fact that amyloid plays a critical role in Alzheimers, says immunologist and aging expert Richard J. Hodes, director of the National Institute on Aging in Bethesda, Md. Since taking on the role in 1993, Hodes has helped set the course for U.S.-funded Alzheimers research, allocating support for promising projects, including studies happening in Colombia.

The Colombian family, 5,000 members strong, includes an estimated 1,000 or so people who carry the Paisa mutation in the presenilin 1 gene. Their involvement in the research has been invaluable. Access to hundreds of people known to be at high risk for the disease allows scientists to study how Alzheimers unfolds, particularly at its earliest stages, and has led to reports of early signs of Alzheimers, both in the brain and the blood. Family members have gone to great lengths to help, walking or taking a bicycle to the nearest bus stop, and then taking a bus to a train, for many hours, to come to the clinic, Hodes says.

During Hodes recent visit to the Medelln area, a resident told him how the disease is just a part of their lives: If I have the disease, I know that my family, my brother and my sister, will take care of me. And if I dont, I will take care of them.

When Colombian researchers learned of the woman who stayed sharp until her 70s, they arranged for her to travel to Boston in the summer of 2016, accompanied by family members and a research assistant. There, neuroimaging researcher Yakeel T. Quiroz and her colleagues used brain scans to measure levels of amyloid and other markers of brain health, including another Alzheimers-related protein called tau, which can tangle up inside nerve cells.

Those scans revealed a brain loaded with amyloid, says Quiroz, of Harvard Medical School. This woman had most likely been accumulating amyloid for decades. On a scale commonly used to quantify amyloid in the brain, she scored 1.96, well above the threshold of 1.2 that signifies extensive amyloid buildup. Her score was, pretty much the highest that we have seen in anybody we have scanned so far, Quiroz says.

Genetic analyses revealed that the woman had whats called the Christchurch mutation in both copies of her APOE gene. Further tests suggested that this mutation, named for the New Zealand city where it was first found, was shielding her from the disease. The fact that the woman had huge amounts of amyloid in her brain, yet didnt seem impaired until her 70s, is extremely surprising, interesting, provocative and potentially very, very informative, Hodes says.

Scientists need to do more work to confirm that the APOE Christchurch mutation protected her brain. Still, the results reveal a simple truth, Hodes says. Amyloid itself is not necessarily sufficient to cause dementia.

Studies outside of the Colombian family also make clear that amyloid isnt the whole story. Other cellular actors contribute to the death of nerve cells and memory loss that Alzheimers brings. Nerve cellclogging tangles of tau and other signs of brain illness are tightly linked to brain decline, research from many studies has shown. Thats reflected in observations from a study of 480 people age 60 and older who live around Rochester, Minn.

These people, none of whom showed signs of dementia, were randomly chosen to be invited into the study, an unbiased selection that offered researchers a glimpse of brain health in the wider population.

To find out which brain changes best predict future memory loss, neuroradiologist Clifford R. Jack Jr. of the Mayo Clinic in Rochester and colleagues tested volunteers memory performance while measuring their amyloid levels and other brain signals. Amyloid seemed to be closely involved in memory decline over about five years but only in the right context, the team reported in June 2019 in JAMA.

Without either of two other troublesome markers tau tangles or brain shrinkage amyloid didnt predict memory loss. In other words, amyloid might be setting up the shot, but then it passes the ball.

Amyloid in the head is the first stage of what will ultimately lead to full-blown Alzheimers disease, Jack says. But there can be a lot of time between that early stage of amyloid accumulation and the development of symptoms.

Among the Colombian family members, that interval lasts around 10 to 15 years. The same is roughly true for people with the sporadic form of Alzheimers. But for the woman described in the report in Nature Medicine, that lag seemed twice as long.

That suggests that at least its possible to live with amyloid not just for 15 years, but for many decades, says Paul Aisen, director of the University of Southern Californias Alzheimers Therapeutic Research Institute in San Diego. Living healthy longer: Thats very exciting.

The protective effect of the womans mutation seems to come from an extremely specific change. In the Christchurch variant, a single spot in the APOE gene is tweaked. The resulting protein has a serine amino acid swapped in for the standard arginine.

The swap prevents the APOE protein from binding to some sugar-dotted proteins called heparan sulfate proteoglycans, or HSPGs, experiments on the isolated proteins revealed. Earlier studies showed that HSPGs may promote amyloid accumulation and nudge nerve cells to slurp up more toxic tau.

But to misbehave, HSPGs might need to partner with the APOE protein. The Christchurch mutation could have protected the womans brain by scrambling that nefarious relationship, the researchers suspect. Without that specific connection between APOE and HSPGs, the disease process gets stalled, Arboleda-Velasquez says. This really puts a block on the cascade of events.

Fleshing out the APOE proteins normal biological cascade, and how that changes with the Christchurch mutation, is going to allow for much more finely targeted drug development, says Aisen, who also works as a consultant for Biogen, a biotechnology company in Cambridge, Mass. The company is developing an amyloid-targeting drug called aducanumab and is expected to apply for approval from the U.S. Food and Drug Administration this year (SN: 1/18/20, p. 8).

As one of the strongest genetic risk factors for dementia, the APOE gene has long been scrutinized as a possible target for Alzheimers drugs. People who carry a version of the gene called APOE4 have a higher risk of Alzheimers.

The APOE2 version dramatically lowers the risk, Quiroz, Arboleda-Velasquez and colleagues report in preliminary research posted online November 2 at medRxiv.org. APOE3 usually brings an average risk of Alzheimers, with the notable exception of the version with the Christchurch mutation carried by the Colombian woman.

In the general population, old age is the biggest risk factor for Alzheimers. As the number of older people balloons, so too will the number of people with dementia. By 2050, an estimated 13.8 million people in the United States will have Alzheimers. Worldwide, an estimated 50 million people have dementia; Alzheimers accounts for the bulk of those cases.

The family in Colombia continues to help. A clinical trial testing a drug that is designed to lower amyloid is under way in Colombia. People who have the Paisa mutation but have not shown Alzheimers symptoms, as well as people without the mutation, are receiving the drug. The drug, crenezumab, is an antibody thats thought to mark amyloid for destruction by immune cells. Its being developed by Roche/Genentech.

Quiroz and her colleagues also plan to follow the Colombian woman and other members of the family over time, as part of a research exchange between Fundacin Universidad de Antioquia in Medelln, which has led the studies on this family, and Massachusetts General Hospital in Boston.

Each month, the project, called COLBOS, for Colombia-Boston, flies a new group of about five adult participants to Boston for extensive evaluation, including thinking and memory tests, brain scans and measurements of smelling ability, fitness and music perception. Participants being studied in Colombia are as young as 9 years old.

The project may yield insights about how Alzheimers takes hold early on. But in a way, the initial trigger might not even matter. It could be that the cause or more likely, causes of Alzheimers might ultimately be poor targets for drugs, Arboleda-Velasquez says.

People with loved ones suffering from Alzheimers, including the Colombian family, dont necessarily care what causes the disease, Quiroz says. They are more interested in seeing if there is anything that can help them to get better. Thats what the patients and families are waiting for.

The rest is here:
How one woman became the exception to her familys Alzheimers history - Science News

Read More...

Genetics and lifestyle can be obesity risks – Coshocton Tribune

Sunday, January 26th, 2020

Emily Marrison, Columnist Published 11:00 a.m. ET Jan. 25, 2020

For better and for worse, we all inherit particular characteristics from our parents.

Maybe its our mothers eyesor maybe our fathers temper. Some of that is directly the result of the DNA weve receivedand some of it comes from the influence they exerted in our environment.

Emily Marrison(Photo: Submitted)

When it comes to our health and wellness, it can be challenging to determine whether nature or nurture has more of an impact. In some cases, it may not really matter. But when it causes you to feel powerless or apathetic about how much you can change your condition, it definitely matters.

Results of a long-term study were recently published in the Journal of the American Medical Association of Cardiology. The study tracked data on more than 2,500 Americans who were followed for decades from young adulthood in 1985 to 2010. One of their findings is that body mass index (BMI) in youth appears to be the best predictor of long-term obesity risk.

There have been other studies in recent years that have identified certain genes that are believed to be responsible for a person becoming overweight and obese. There are rare inherited causes of obesity, but this is not the case for the majority of the population. This study suggests that daily lifestyle is the more important factor for determining our weight.

When we look at the BMI of children, this is showing the result of genetics as well as environment. The genes we inherit can certainly make us more susceptible to weight gain, but that doesnt mean it is inevitable. Hopefully, this research can empower people to know that being obese doesnt have to be someones destiny. Their healthy lifestyle choices the foods they eat, their portion sizesand physical activity can result in a better quality of life.

According to the National Heart, Lungand Blood Institute, being overweight or obese increases your risk of developing heart disease, high blood pressure, type 2 diabetes, gallstones, breathing problems and certain cancers. A European study linked obesity to a nearly six-fold increased risk of developing type 2 diabetes.

If you are looking for ways to learn more about healthy lifestyle choices while managing diabetes, theOSU Extension has some great resources available. I am pleased that we will be partnering with the Coshocton Regional Medical Center this April to offer Dining with Diabetes. This is a cooking school and nutrition education program designed for people with diabetes and their family members or caregivers.

Dining with Diabetes will be held from 5:30 to 7:30 p.m. Mondays April 6 to 27 at Coshocton Regional Medical Center, 1460 Orange Street, Coshocton. The cost of the program is $20 per person and includes all four classes, educational handoutsand small-sized meals that feature a variety of recipes. You are encouraged to also register a support person to attend with you for an additional $5. You can find more details and registration information at coshocton.osu.edu.

Today, Ill leave you with this quote from Billy Graham, When wealth is lost, nothing is lost; when health is lost, something is lost; when character is lost, all is lost.

Emily Marrison is an OSU Extension Family & Consumer Sciences Educator and may be reached at 740-622-2265.

Read or Share this story: https://www.coshoctontribune.com/story/news/local/2020/01/25/genetics-and-lifestyle-can-obesity-risks/4562639002/

See the article here:
Genetics and lifestyle can be obesity risks - Coshocton Tribune

Read More...

Study sheds light on the genetics of hibernation – Scope

Sunday, January 26th, 2020

When ground squirrels hibernate, their body temperatures drop dramatically -- roughly from 98.6 to 39.2 degrees Fahrenheit for weeks at a time.They also stop eating and enter into a state of torpor to conserve energy; their baseline physiology -- including metabolic, respiratory and heart rates -- slows to approximately 1-3% of normal function.

Arousing from that torpor and returning to their normal temperatures is an intense process akin to a heart attack, as the ground squirrels' heart rates essentially skyrocket so they can rewarm in just a couple of hours. Yet the squirrels emerge from hibernation undamaged and even protected from some conditions that are harmful to humans, such as heart attack and stroke, bone and muscle atrophy and metabolic diseases.

Though environmental factors, such as day length and temperature, influence when ground squirrels begin hibernation, individual genes also affect their behavior. In a recent paper published in Communications Biology, Stanford researchers Katharine Grabek, PhD, Carlos Bustamante, PhD, and their colleagues made strides in pinpointing the role of genetics in driving these large shifts in behavior and physiology -- insights that Grabek said could potentially be helpful in understanding humans.

"To hibernate, we think ground squirrels are using common mammalian genes shared with humans, but they are just utilizing them differently," she told me. "By identifying these genes, we can find new therapeutic avenues for human diseases."

To investigate, Grabek, Bustamante and their team took liver samples from 153 squirrels that were shipped to them by an OshKosh, Wisconsin breeder. They determined the genotype of each, and charted the familial relationships among the animals.

Then the scientists recorded the first day each subject's body temperature dropped, signaling the onset of hibernation. From there, they looked for patterns connecting the timing of hibernation with certain gene variants. They also applied a genome-wide association study -- which provided information about genetic mutations throughout each squirrel's genome to identify which genes statistically were most likely to be associated with the onset of hibernation.

The researchers found that hibernation onset in ground squirrels is strongly governed by genetics -- that is, after accounting for known environmental factors, the remaining differences in when squirrels started hibernation were due solely to genetic variation. The team also identified two genetic variants near FAM204A and EXOC4 -- both are genes shared with humans -- that are most likely responsible, as squirrels with these two mutations in their DNA went into hibernation later in the year than squirrels without the mutations. Twelve other variants also are likely associated with the onset of hibernation, according to the study, but the statistical values were not strong enough to be conclusive.

Grabek told me she was surprised by the definitive nature of the results: "I was expecting that there would be a genetic component explaining some of the variation in hibernation onset," she said, "I just didn't expect so much of variation in timing to be due to genetics."

Identifying genes behind the controlled process of torpor and hibernation could ultimately help scientists understand and develop treatments for conditions and diseases in humans, Grabek told me:

For example, prior to hibernation, the squirrels spend most of their days eating food and accumulating a lot of body fat. Then at the onset of hibernation, they stop eating altogether and, instead, use their fat reserves as a fuel source while they hibernate. Since the genes controlling this dramatic shift in food intake are likely shared with humans, after we identify them in squirrels, the human forms of the genes could be targeted with drugs to help people lose weight.

Other insights from the genes could help researchers formulate treatments to help people recover from heart attacks or strokes, or to maintain muscle mass during prolonged bouts of bed rest, she said.

Bustamante shares Grabek's excitement. He told me, "We believe this is the first of many insights that can be gleaned from studying the molecular basis of mammalian hibernation. Ultimately, we want to see this work translated into medicines and other therapies for the benefit of humankind."

Photo of a ground squirrel from the study, courtesy of Bryan Roeder and Sandra Martin

See more here:
Study sheds light on the genetics of hibernation - Scope

Read More...

Is the consumer genetics fad over? – MIT Technology Review

Sunday, January 26th, 2020

The CEO of 23andMe told CNBC her company will lay off 100 people as sales of its direct-to-consumer gene tests slump.

This has been slow and painful for us, CEO Anne Wojcicki told the website, which estimated the cuts would pare about 15% of the company's staff.

Boom times: Sales of DNA tests that tell people their ancestry and health facts started booming a few years ago, propelled by TV and Internet ads hawking the promise that people could gain unique insights from their genes.

During 2018, the total number of people who had ever bought the tests doubled, swelling the databases of 23andMe, Ancestry, and several smaller companies to over 26 million people altogether.

The bust: Now, all signs are that sales of the $99 consumer tests slowed dramatically in 2019.

Our own calculations suggest the largest companies sold only four to six million of them, meaning the databases would have grown by just 20% during the year. That would have been the slowest growth rate for the DNA test industry ever.

Uncertain causes: It's not clear why consumers stopped buying tests in droves. It could be that the market is tapped out, and there aren't many people left curious to learn what percent French or Nigerian they are, or whether they are at risk for going bald.

Others may have concerns about their DNA data staying private, since police have started accessing smaller ancestry databases to carry out genetic manhunts.

Ancestry, which maintains the largest database with more than 16 million people, did not answer questions about whether it had seen a sales slowdown. Last year, Ancestry introduced new health offerings in what some analysts saw as a bid spark a "re-testing" market, or coaxing consumers to pay for an additional test.

Read more here:
Is the consumer genetics fad over? - MIT Technology Review

Read More...

Children’s graves reveal genetic diversity of ancient West Africa – Cosmos

Sunday, January 26th, 2020

By Dyani Lewis

Remains from an ancient gravesite in Cameroon have opened a window into the world of the people who lived in western central Africa before farming and herding became widespread.

Africa is the ancient homeland of our species, and the genetic diversity across the continent is unmatched anywhere else on the planet, yet only a handful of sites bearing human fossils have successfully yielded ancient DNA, which is essential for grasping the genetic make-up of prehistoric Africans.

DNA rapidly degrades in tropical conditions and burials were rare prior to the Iron Age, which started around 1500 BCE in Africa.

There's a tremendous amount of genetic diversity in the past in Africa that we have not been able to see by sampling modern populations, says archaeologist Mary Prendergast from Saint Louis University, Spain, one of the lead authors of a paper in the journal Nature.

Thats where the Shum Laka rock shelter comes in. The site, which lies in the Grassfields region of western Cameroon and bears clear signs of use by human foragers from as long as 30,000 years ago, is unique, says Prendergast.

Eighteen people, mostly children, were buried there during two periods 8000 and 3000 years ago respectively. Both communities were hunter-gatherers, and by the later time period they were using pottery and relying heavily on fruit picked from nearby forest trees.

These time points book-end an important transition period from the late Stone Age to the Iron Age, says Prendergast, during which humans took up farming and herding.

Linguists have also long thought that the Grassfields region could be the birthplace of the Bantu language group. Bantu languages spread across sub-Saharan Africa from about 4000 years ago and are today spoken by more than a third of Africans.

There's been a century of discussion about where Bantu languages originated and how they spread, says Prendergast.

Mark Lipson, from Harvard Medical School, and colleagues extracted then analysed ancient DNA from the DNA-rich inner ears of four children buried at Shum Laka two from each period to see whether they were the ancestors of modern-day Bantu speakers.

But that turned out not to be the case. None of the children who were all related to each other were related to present-day Bantu speakers.

Instead, they were part of a population that has almost been completely replaced. About two-thirds of the Shum Laka ancestry is from a previously unknown line that is distantly related to present-day West Africans. The other third is from a lineage related to present-day central African hunter-gatherers.

Bantu languages may still have their origins in the Grassfields region, says Prendergast, but the Shum Laka children arent part of that ancestral population.

Lipson and his colleagues also used the ancient genomes of the four children, along with genomes from modern-day Africans, to cast their focus much further back in time.

An adolescent male from the rock shelter carried a rare genetic variant of his Y chromosome that is today found almost exclusively in western Cameroon, close to Shum Laka.

A previous study proposed southern Africa as the homeland of the oldest human lineage, but the rare Y chromosome suggests that a lineage contributing to central African hunter-gatherers is just as ancient, cleaving off from other African branches some 250,000-200,000 years ago.

At the time of the split, four lineages emerged. Three are ancestral to present-day central African hunter-gatherers, southern African hunter-gatherers, and all other modern humans. The fourth, a previously unknown ghost population, contributed a small amount of ancestry to both western and eastern Africans.

Another split occurred around 80,000-60,000 years ago, leading to genetic lines that are present in the majority of present-day eastern and western African and all non-Africans.

Compared to Europe or Asia, African ancient DNA studies are in their infancy.

It's incredible what we've learned in the past few years, says Prendergast. But, she adds, we're just scratching the surface of what the human landscape would have looked like before the spread of food production.

See original here:
Children's graves reveal genetic diversity of ancient West Africa - Cosmos

Read More...

Environmental and genetic determinants of plasmid mobility in pathogenic Escherichia coli – Science Advances

Sunday, January 26th, 2020

INTRODUCTION

The spread of antibiotic resistance is outpacing the development of new antibiotics. On average, new antibiotics cost upward of $500 million USD and take 10 years to develop, only to have widespread resistance appear in less than 3 years (1, 2). Horizontal gene transfer (HGT) is often implicated in this rapid decline in efficacy, mobilizing reservoirs of resistance long established in the environment by natural antibiotic producers (3). In this way, targeting mobilization to restore antibiotic efficacy may be more successful than trying to eliminate resistance outright (4, 5).

Conjugation, the direct transfer of DNA from a donor to a recipient, is considered the HGT mechanism most responsible for mobilizing resistance among Enterobacteriaceae (2, 6). Conjugative plasmids are exchanged across broad host ranges, harbor resistance to virtually all antibiotics, and may be maintained in hosts with little cost, or in spite of costs, to fitness (7, 8). Furthermore, resistance genes tend to cluster on plasmids, allowing acquisition of multidrug resistance in a single transfer and making antibiotic selection for one now select for all (2).

Modulating conjugation to curtail the spread and maintenance of resistance requires an understanding of the environmental and genetic factors underlying plasmid mobility. Multiple factors have been proposed, including nutrient levels (9, 10), cell-cell signaling (1113), and even antibiotics (11, 1417), potentially accelerating the spread of resistance. Entire environments (e.g., animals, sewage, and biofilms) have also been labeled conjugative hotspots, uniting compatible donors, recipients, and plasmids under conditions that encourage HGT (6). However, growth dynamics are often coupled with conjugation modulation, making conjugation-specific effects difficult to interpret (Fig. 1A). For instance, in contrast to the prevailing conclusion that antibiotics promote conjugation, a recent study found no notable antibiotic effects when controlling for growth dynamics (9). Together with limited strain diversity and low-resolution genomic analysis, this ambiguity in conjugation quantification leaves the determinants of plasmid mobility in question.

(A) The influence of environmental and genetic factors on conjugation is confounded by growth dynamics between donor (red), recipient (blue), and transconjugant (purple) populations. By decoupling conjugation modulation from growth dynamics, we can identify and use the determinants of plasmid mobility to fight antibiotic resistance. (B) Assembling a library of natural isolates with quantifiable rates of conjugation is a substantial undertaking. Starting from a library of 219 clinical E. coli pathogens from patient bloodstream infections, we screened for the ability to transfer -lactam resistance commonly found on plasmids native to the Enterobacteriaceae family. Approximately 25% of the carbenicillin-resistant (CarbR) isolates exhibited detectable transfer to chromosomally kanamycin (KanR) or chloramphenicol (CmR)resistant recipients. These and seven extended spectrum -lactamase (ESBL) donors were subsequently used to examine environmental and genetic determinants of plasmid mobility. (C) The diversity present in the E. coli pathogen library is maintained through conjugation screening. A phylogenetic tree of the library was constructed from 200 genome assemblies (BioProject accession nos. PRJNA290784 and PRJNA551684) to reveal the breadth of our analysis throughout each phase of screening. Genome assemblies for the remaining 19 isolates were either unavailable or of insufficient quality. E. coli strain EC958 (GenBank accession no. HG941718.1) was used as a reference genome for alignment. Isolates are color labeled by their final phase. Major multilocus sequence types (5 isolates in common) present in the library are highlighted in gray.

To address these issues, we carried out the largest-scale analysis of conjugation phenotype paired with genotype in clinical Escherichia coli pathogens known for plasmid-borne multidrug resistance. In doing so, we introduce a new method for quantifying conjugation phenotype that increases throughput and sensitivity while reducing ambiguity due to growth dynamics. In general, we find that antibiotics exert little to no effect on conjugation efficiency, with one exception displaying significant promotion in the presence of macrolides and chloramphenicol (Cm). Conversely, conjugation efficiency strongly correlates with plasmid maintenance as indicated by the incompatibility (Inc) group. As our understanding of the environmental and genetic determinants of conjugation efficiency improves, modulation of HGT may become an important new tool for the fight against antibiotic resistance and control of bacterial evolution at large.

To study conjugation modulation, we focus on a library of 219 E. coli isolates collected from patient bloodstream infections at Duke University Hospital over 2002 to 2014. The Enterobacteriaceae family of Gram-negative bacteria serves as an ideal model to study HGT. Worldwide, it causes hundreds of millions of infections per year and harbors plasmids bearing multidrug resistance, most notably extended-spectrum -lactamases (ESBLs) that cleave the most widely used class of antibiotics (18). Of these 219 isolates, 197 were chosen at random from the Duke Bloodstream Infection Biorepository (BSIB), and the remaining 22 were chosen for multidrug resistance.

We first screened the isolates for kanamycin (Kan) and Cm susceptibility to contrast with established MG1655 E. coli plasmid recipients with Kan or Cm resistance (Fig. 1B). All but 18 (8%) isolates were susceptible to at least one antibiotic, with 69 (32% total, 25% random) exhibiting resistance to Kan (50 g/ml) and 31 (14% total, 13% random) exhibiting resistance to Cm (50 g/ml). With Kan or Cm susceptibility established for each isolate, we screened for the ability to transfer -lactam resistance to susceptible recipient E. coli. Of the Kan- or Cm-susceptible isolates, 143 were found to be resistant to carbenicillin (100 g/ml; Carb). Clinical data from the BSIB indicating susceptibility to -lactam antibiotics other than Carb were used to infer Carb susceptibility for 51 isolates. The 143 Carb-resistant isolates were then tested for the ability to generate Carb- and Cm/Kan-resistant transconjugants under dual-antibiotic selection. Subsequent rounds of dilution and repeat selection were performed to ensure that any growth under dual selection was from transconjugants, instead of donors or recipients. Of the 143 Carb-resistant isolates tested, 35 (24% total, 25% random) were capable of producing Carb- and Cm/Kan-resistant transconjugants under the experimental conditions. Phylogenetic analysis revealed that much of the genetic diversity present in the starting library was maintained throughout screening (Fig. 1C). Only plasmid-free recipients were used to prevent incompatibility issues with unknown isolate plasmids and retrotransfer, which generates two transconjugants per conjugative pairing (19).

In the absence of growth dynamics, the conjugation efficiency (), or the rate constant of conjugation, can be determined as=T/(DRt)where D, R, and T, respectively, represent the densities of the donor, recipient, and transconjugant populations after a short incubation time (t) (9). This relationship can be disrupted via selection (e.g., media and antibiotics) that leads to differential growth or death (Fig. 1A). To avoid these confounding factors, we restrict growth during conjugation (fig. S1). Under these conditions, D and R can be readily determined from starting cultures, which poses no technical challenges.

Quantifying T after incubation traditionally relies on selective plating from mixed culture, which is error prone and tedious. Relatively small T and variation over multiple orders of magnitude make this more challenging, and restricting growth exacerbates these issues. To overcome these limitations, we developed a simple, yet robust method that allows transconjugant outgrowth for improved quantification. Consider the exponential growth of the transconjugant starting from an initial density of T0. T0 is uniquely related to , the time for the population to reach a set threshold TClnT0=lnTCwhere is the specific growth rate (Fig. 2A). With proper calibration, this relationship provides a high-throughput approach to quantify T0 by tracking bacterial growth via optical density (OD) in a plate reader. Experimentally, we establish a standard curve relating T0 and by growing transconjugant cultures from known starting densities. The standard curve is then used to determine T0 in samples subjected to the same growth conditions. For the same TC, the standard curves for different transconjugants (generated from different donors, but the same recipient) were highly similar to each other, reflecting a similar for these strains (fig. S2A). For the same transconjugant, we found quantification to be robust to the choice of OD thresholds that fall in the logarithmic growth phase (fig. S2B).

(A) The principle of time to threshold quantification. Consider the exponential growth of the transconjugant from an initial density T0 (top panel). The time () required for the population to reach a set threshold (TC) is uniquely determined by T0 and the specific growth rate (). This defines a log-linear relationship between T0 and : lnT0 = ln TC (bottom panel). (B) Quantification of T0 is complicated by the presence of donor and recipient cells. Top panel: Although strong antibiotic selection is applied against donor and recipient cells during transconjugant outgrowth, death is not instantaneous (i.e., conjugation may still occur). Bottom panel: Modeling reveals conjugation of variable efficiency () during outgrowth causes a deviation from the log-linear relationship. This effect is amplified with smaller T0, where transconjugants produced from outgrowth conjugationnot outgrowth alonemay comprise a sizeable proportion of the total transconjugant population. (C) Correcting for outgrowth conjugation. Top panel: The growth contribution from the transconjugant alone can be approximated by the difference (N) between the growth curves originating from the conjugation mixture (T0 > 0) and conjugation control (T0 = 0). Darker curves represent higher T0. Bottom panel: Using N, the log-linear relationship between T0 and is maintained even in the presence of conjugation during outgrowth. (D) Applying the time to threshold method to experimental data. T0, spanning six orders of magnitude, maintains a strong correlation (R2 > 0.99) with from a OD threshold. Darker curves represent higher T0.

The reliability of the standard curve depends on a critical assumption: All the growth originates from the transconjugants at time zero. This can be approximated by imposing strong double selection to suppress growth of donor and recipient cells during outgrowth. However, this suppression is not instantaneous, and new transconjugants can still be produced through conjugation (Fig. 2B).

To examine this contribution, we built a kinetic model that accounts for growth and conjugation dynamics during T outgrowth. In the absence of conjugation during outgrowth ( = 0), the model predicts a linear relationship between lnT0 and , similar to the case where exponential growth is assumed (Fig. 2A). At > 0, the correlation deviates from the log-linear relationship, where the same T0 would correspond to a smaller than what would be expected for = 0. A larger leads to a larger deviation. Under this condition, a given value of would lead to an overestimate of T0 if the log-linear relationship is directly used. However, we found that the deviation from outgrowth conjugation can be eliminated by subtracting the growth curve produced by parents mixed only at the start of outgrowth, yielding N value (Fig. 2C). The early phase of N provides an approximation of T0 growth in the absence of outgrowth conjugation, and simulated standard curves established using N do not significantly deviate from the log-linear correlation even in the presence of substantial outgrowth conjugation. Experimental results using OD to approximate N emulate the model, and displays a strong log-linear correlation with T0 over multiple orders of magnitude (Fig. 2D and fig. S2).

Together with seven previously identified ESBL donors (20), we measured the effect of antibiotics on conjugation in clinical E. coli pathogens (Fig. 3). We display the difference in time to threshold () between antibiotic and no-antibiotic control conditions to better reflect conjugation effects across isolates and minimize unnecessary data processing. The absolute magnitude of is the result of many variables that affect growth rate (e.g., conjugation and media conditions). Five antibiotics with different mechanisms of action were tested, covering inhibition of translation, DNA replication, and cell wall synthesis. Three sublethal concentrations were used, based on the 50% inhibitory concentrations (IC50) of the susceptible recipients, to capture concentration-dependent effects (9). Donor minimum inhibitory concentrations (MICs) and IC50s are shown in fig. S3A and table S3. We erred on the side of concentrations too low for the multidrug-resistant pathogens to ensure the survival of the recipients and subsequent transconjugants. Because of experimental constraints chosen to restrict background conjugation and growth dynamics, donors with conjugation efficiencies less than 1016 produced too few transconjugants for quantification.

The effect of five antibiotics on conjugation in clinical E. coli pathogens was assessed via the time to threshold method. Antibiotics of differing therapeutic mechanism were dosed in three concentrations (0.5, 1, and 2) based on 50% inhibitory concentrations for a MG1655 E. coli recipient standard. IC50 values for Carb, Cm, Kan, erythromycin (Ery), and Norf were as follows: 1.91, 1.92, 2.13, 20.20, and 0.05 g/ml. Displayed are averages of triplicate measurements SE, and normalized by subtracting the no-antibiotic control . Promotion of conjugation is indicated by < 0, while > 0 indicates inhibition. Only GN02766 displayed major modulation of conjugation when exposed to Ery (all concentrations, P < 0.01, Tukey post hoc test) and Cm (2 concentration, P < 0.05). Results from two separate GN02766 experiments are shown.

A global analysis of variance (ANOVA) revealed significant effects for both antibiotic isolate [F(94,1374) = 4.96, P < 0.0001] and antibiotic concentration isolate [F(282,999) = 2.28, P < 0.0001] interactions, prompting post hoc testing via Tukey post hoc test. We find that the majority of pathogen donors display little to no significant antibiotic modulation of conjugation, and where there is statistically significant , it corresponds to approximately less than a fivefold change in transconjugants. In addition, no correlation was seen between donor IC50 and (fig. S3B). However, isolate GN02766 exhibited a drastic increase in conjugation when exposed to certain antibiotics. GN02766 produced ~3.5-fold more transconjugants in the presence of 2 IC50 of Cm [t(7.5) = 3.7, P < 0.05, Welchs modified t test], while all concentrations of erythromycin (Ery) yielded up to 31-fold more transconjugants [t(8.5) = 18, P < 0.0001] (fig. S4A). Of the five antibiotics tested, only Cm and Ery are considered bacteriostatic and both inhibit translation via the 50S ribosomal subunit, suggesting a common mechanism. Kan, which also inhibits translation, did not have an effect, possibly due to bactericidal effects, targeting the 30S ribosomal subunit, or concentration dependence.

To distinguish a general bacteriostatic effect from a macrolide- and phenicol-specific mechanism, we retested GN02766 with azithromycin (Az) and sulfamethoxazole (Sm). Solvent- and donor-recipient strain interactions were also tested and ruled out (fig. S4B). Also a macrolide, Az differs from Ery in its 15-membered ring structure. Sm is bacteriostatic, but differs from Cm and Ery in mechanism of action by inhibiting folate and, subsequently, DNA synthesis. Az produced a virtually identical ~31-fold increase in transconjugants to Ery [t(8.4) = 15.5, P < 0.0001], while Sm produced no significant effect [t(2) = 0.04, P = 0.76] (fig. S4C). Together, these results suggest macrolide- and, to a lesser degree, phenicol-specific promotion of conjugation in GN02766.

To reveal plasmid genotype and identify features associated with antibiotic modulation and conjugation efficiency, we performed whole-genome sequencing on 19 isolates of varying conjugative phenotypes (BioProject no. PRJNA551684). For large plasmids, standard plasmid purification kits yielded poor results, and sequence assembly from short reads has been shown to be difficult. Instead, we used long-read sequencing from Pacific Biosciences (PacBio) capable of accurately discerning mobile elements from the chromosome. As predicted from empirical findings, plasmid-borne -lactamases were detected in each isolate. A summary of sequencing results can be found in table S2, complete with plasmid number, size, replicon (Inc), mobility relaxase (MOB), and identified resistances present in each isolate.

GN02766 was found to harbor two plasmids: p2766-1, a 137-kb plasmid identified as IncFIB/IncFII/Col156, and a 29-kb plasmid without designation. Without identifiable MOB or transfer (tra) machinery on the 29-kb plasmid, only p2766-1 appears to be mobile and carries a -lactamase, blaSHV, relevant to our conjugation assay. By comparing the plasmids of isolates displaying no antibiotic modulation to p2766-1, we can identify unique features that may give insight into how macrolide and phenicol antibiotics promote conjugation. Here, we show 24 of these plasmids that bear the greatest similarity to p2766-1 (nucleotide identity, 70%), although much diversity remains (Fig. 4). Much of the tra region for conjugation was conserved across plasmids with traJ, a key activator of tra gene expression, as a notable exception. We also aligned plasmid sequences to p168-1, the closest match to p2766-1 that displayed no antibiotic modulation, to see what common features p2766-1 might lack (fig. S5). No major commonalities among the majority of plasmids appear to be lost, suggesting the conjugation phenotype of p2766-1 may be gained instead.

Plasmid sequences from strains displaying no antibiotic modulation were aligned to p2766-1 via BLASTn and BLAST Ring Image Generator (BRIG) (47). Nucleotide identity 70% is indicated by a band colored according to the Inc group, with darker shading corresponding to higher sequence match. Blank regions indicate <70% nucleotide identity. Inner GC content plots, size map, and outer coding sequences (CDSs) are for p2766-1. Antibiotic resistance genes are highlighted in red, and transposon repeat region in gray. Notable features include five-plasmid maintenance systems (pemKI, relBE, hok-sok, srnBC, and parAB), a mobilized enterotoxin and colicin J receptor operon (cjrABC-senB), and five consecutive tnpA transposon repeats carrying blaSHV.

There are several features of note on p2766-1: five plasmid maintenance systems, a mobilized enterotoxin and colicin J receptor operon, and five consecutive tnpA transposon repeats. Of the five plasmid maintenance systems, four function through addiction (pemKI, relBE, hok-sok, and srnBC), with toxins that kill daughter cells if they lack the plasmid-encoded antitoxin. For comparison, ESBL-producing strains only have 2.38 addiction systems on average with a range of 0 to 6 (21). The fifth maintenance system, parAB, aids in plasmid segregation (22). In common with two other IncFIB/FII/Col156 plasmids, p2766-1 also includes cjrABC and senB, which play important roles in E. coli pathogenesis (23). Unique to p2766-1 is a repetitive region of five consecutive tnpA transposon repeats, each bearing a deoR, blaSHV, recF, and truncated lacY gene, respectively, encoding a transcriptional repressor of sugar metabolism (24), ESBL, DNA recombination and repair protein, and -galactoside permease. This repetitive region is genuine as we see no decrease in sequence coverage indicative of assembly error (fig. S6). It is particularly interesting that deoR is implicated in limiting plasmid copy number (25), and recF facilitates recombination (26, 27) and mutagenesis (28). A closely related IS26-flanked blaSHV-5 amplicon was found to spread via recombination, not transposition, with up to 11 consecutive amplicons forming under high -lactam antibiotic stress (29).

The conjugation phenotypes we observed with clinical E. coli pathogens can arise from the plasmids, chromosomes, or both. To control for chromosomal effects, we used Kan-susceptible DA28102 transconjugants (denoted as strain #T) as donors to Kan-resistant fAYC002 recipients. With plasmids as the only differences between the transconjugants, any change in conjugation efficiency may therefore be attributable to the plasmids themselves. In this way, the macrolide promotion seen in GN02766 appears to be transferrable, with 0.5 and 1 IC50 of Ery significantly reducing (P < 0.0001 and P < 0.05, respectively, Tukey post hoc test) when 2766T is used as a donor (fig. S7A). No effect was seen with other DA28102 transconjugants, further supporting a p2766-1based mechanism (fig. S7B). Donor, recipient, and growth conditions likely play a role, however, as the degree of macrolide promotion was diminished in 2766T.

Compared to the maximum 31-fold change we saw with antibiotics, the baseline conjugation efficiencies of plasmids have the potential to differ over several orders of magnitude. Even relatively minor changes, such as growth stage or nutrient concentration, can cause orders of magnitude shifts in conjugation efficiency (9, 10, 30). Here, we focus on the origin of these more fundamental distinctions between conjugative plasmids. Plasmids are typically classified by two major systems: Inc group and MOB relaxase. Inc groups are based around plasmid maintenance (e.g., replication controls), where two plasmids of the same Inc group could not be stably maintained in the same cell (31). MOB relaxase typing, centered on the protein that nicks oriT to initiate conjugative transfer, was proposed to avoid problems in the Inc system, such as multiple replicons or maintenance systems that differ greatly in how they work (32).

MOB relaxases are thought to accurately represent tra machinery based on high congruence between their phylogenetic trees (32). Therefore, we wondered whether MOB relaxase might correlate with conjugation efficiency with the donor, recipient, and environment held constant. However, we find that Inc groups are more predictive of a plasmids conjugation efficiency than MOB relaxase [F(6,53) = 111.6, P < 0.0001 versus F(2,57) = 1.26, P = 0.291, respectively, ANOVA; Fig. 5). The strong correlation between the Inc group and conjugation efficiency remains when the 2766T outlier is removed [F(5,48) = 62.36, P < 0.0001]. Inc groupings were made at the most general level (i.e., IncF includes IncFI, FII, etc.) for plasmids carrying a -lactamase marker by which we measured conjugation. Given the apparent difference between the IncF/Col and IncF groups, we paid particular attention to mobilizable colicin plasmids that can transfer alongside the -lactamase (i.e., from GN05696 to 5696T and beyond). Further subdivisions in Inc groups and MOB types may yield greater resolution between conjugation efficiencies. Our results suggest that the factors involved in plasmid maintenance play a more significant role in its transfer than previously thought.

Plasmids carrying -lactamases from clinical E. coli pathogens were classified by Inc grouping and MOB relaxase families. To eliminate host effects, conjugation efficiencies were only measured using DA28102 transconjugants and the fAYC002 recipient. There is no significant difference among conjugation efficiencies when grouped by MOB relaxase (P = 0.291, ANOVA), whereas grouping by Inc is highly significant (P < 0.0001). Individual Inc groups that could not be distinguished from one another at P 0.05 are bracketed. Data were log transformed to normalize variation across orders of magnitude. Error bars represent SD from at least three replicates.

Drawing from the same fundamental principles as quantitative polymerase chain reaction, we developed time to threshold as a simple and effective new method for quantifying plasmid transfer rates in the absence of confounding growth dynamics. The time to threshold method improves upon agar plating in both throughput and sensitivity, returning transconjugant density in as little as 5 hours without the ambiguity from subjective colony counting. Amid conflicting reports for antibiotic modulation of conjugation (9, 11, 15, 16), we find little to no effect in this largest study of conjugation phenotype in clinical E. coli pathogens. The lack of a general antibiotic effect suggests that modulation, if present, arises from more specific interactions and highlights the potentially confounding impact of growth dynamics on conjugation quantification. Yet, even minor modulation of conjugation maintained over time may be sufficient to push plasmids above or below critical maintenance thresholds (7). As more conjugation inhibitors and promoters are discovered, we may begin to harness and incorporate these dynamics into prophylactic strategies that address the source of antibiotic resistance for many pathogens (5).

Isolate GN02766 is an exceptional case of conjugation modulation with the ability to spread antibiotic resistance faster in the presence of antibiotics. Through the time to threshold method, we detect up to 31-fold promotion of conjugation upon exposing GN02766 to macrolides or Cm, both of which target the 50S ribosomal subunit. We link macrolide promotion to a single IncFIB/FII/Col156 plasmid (i.e., p2766-1) bearing five plasmid maintenance systems and tnpA transposon repeats notably encoding deoR, blaSHV, and recF. Unique to p2766-1 and the conjugation promotion phenotype, deoR and recF are involved in suppressing copy number (25) and promoting recombination of plasmids, respectively. Translation inhibition from macrolides and Cm may relieve metabolic suppression from multiple copies of deoR and destabilizing oligomerization from recF (33), increasing p2766-1 copy number, tra gene expression, and, ultimately, conjugation efficiency. As the number of unique -lactamases continues to rise, the potential this transposon offers for blaSHV diversification through gene duplication is concerning (29). Both intra- and intercellularly mobile through recombination and antibiotic-promoted conjugation, this blaSHV transposon represents a threat for the evolution of antibiotic resistance and warrants further study.

Going beyond special cases, understanding the determinants underlying plasmid mobility is critical to predicting how they spread as vehicles of antibiotic resistance and HGT. By removing host and growth variables, we find that Inc groups based on plasmid maintenance appear predictive of conjugation efficiency, whereas MOB relaxase classification does not. This comes as a surprise given MOB relaxases more direct connection to conjugation (32). However, the dominance of MOBF and MOBP among E. coli isolates with detectable conjugation falls in stark contrast to the diversity of Inc groups, suggesting that MOB may dictate plasmid prevalence at a high level (31, 34). The apparent predictive power of incompatibility groups, as ubiquitous features of plasmids, could nevertheless hold considerable value for understanding gene flow through HGT networks, especially if it extends beyond E. coli and the plasmids studied herein. Knowing which plasmids and bacterial strains are most adept at mobilizing antibiotic resistance could better guide strategies to inhibit its spread and improve the life span of antibiotics (5, 7, 35).

A full description of all strains used in this study can be found in table S1.

Unless otherwise stated, donor or recipient strains were cultured at 37C in standard Luria-Bertani (LB; Miller) broth with shaking. Conjugation experiments were performed in M9 media containing casamino acid (2 mg/ml), thiamine (0.1 mg/ml), 2 mM MgSO4, 0.1 mM CaCl2, and 0.4% (w/v) glucose. We call this M9CA media in subsequent text. Rich LB or terrific broth (TB) was used to generate high cell density for subsequent conjugation in M9CA, which was used to control for growth dynamics. Shaking is applied for oxygenation, accurate OD measurements, and breaking up conjugation pili.

We screened the pathogen library for Carb, Cm, and Kan resistance to establish selection markers for conjugation quantification. The BSIB had previously collected disk diffusion data on -lactam antibiotics other than Carb, which we used to infer Carb susceptibility (CarbS) for 51 isolates. Isolates without prior data or with ambiguous resistance were inoculated in 1 ml of LB media in 96deep well plates, covered in a gas-permeable membrane, and grown overnight. Once grown, cultures were diluted 1000 into secondary 96-well plates with and without added antibiotic. Concentrations for antibiotics were as follows: Carb (100 g/ml), Cm (50 g/ml), and Kan (50 g/ml). Secondary plates were then grown for approximately 16 hours. At this point, the OD600 of each culture was measured in a plate reader. Antibiotic culture OD was normalized to corresponding no-antibiotic cultures. Resistance to each antibiotic was defined as 1% maximal growth.

The MIC, which we defined as the first antibiotic concentration to yield 10% or less of the no-antibiotic controls maximum OD600, and IC50 were also determined for plasmid donors tested for antibiotic effects on conjugation (fig. S3A and table S3). Plasmid donors were grown for 16 hours, diluted 100-fold into M9CA with antibiotic concentrations ranging from 0 to 64 g/ml, and then grown for 24 hours before taking endpoint OD600 measurements.

To find pathogens capable of conjugation, we screened Carb-resistant isolates for the ability to transfer -lactamase into Carb-susceptible recipients. Pathogen cultures were grown overnight in 1 ml of LB media with Carb (100 g/ml) in 96deep well plates covered in a gas-permeable membrane. Recipients were grown overnight in 3 ml of LB media with either Kan (50 g/ml) or Cm (70 g/ml). Pathogen isolates were then diluted 10 in LB media and regrown under similar conditions for 2 hours to enter exponential phase. Exponential-phase pathogen isolates and recipient were diluted 100 into 200 l of LB media and mixed 1:1 in a 96-well plate with dual antibiotic selection for transconjugants. Mixed cultures were then covered with 50 l of mineral oil and grown in a plate reader for 24 hours.

After 24 hours of exposure to transconjugant selection, mixed pathogen and recipient cultures that displayed growth were diluted 1000 into fresh LB media with antibiotic selection for transconjugants. These cultures were covered with 50 l of mineral oil and regrown in a plate reader for 24 hours. Cultures that repeated growth under high dilution and strong transconjugant selection were plated on agar also selecting for transconjugants. Individual colonies were isolated and grown overnight in 3 ml of LB media with transconjugant selection. These clonal transconjugant cultures were glycerol stocked for later analysis.

Donor E. coli strains were inoculated into 3 ml of TB media with Carb (100 g/ml) and grown for approximately 16 hours at 37C without shaking. An appropriate recipient MG1655 E. coli strain (CmR DA28102 or KanR fAYC002) with contrasting resistance markers was similarly grown, but with 50 g/ml selecting antibiotic and shaking. Following growth, donor cultures were diluted 10 and regrown for 2 hours to enter the exponential phase. Recipient and exponential-phase donor cultures were pelleted at 2000 relative centrifugal force (rcf) for 10 min at 25C and resuspended in M9CA media, equalizing OD600. At this point, aliquots of donor and recipient cultures were taken for quantification via agar plating and controls for outgrowth conjugation.

Donor and recipient cultures were then mixed in a 1:1 ratio for conjugation, distributed in 500-l volumes, and incubated for 1 hour at room temperature while being exposed to antibiotic or control test conditions. Antibiotic test conditions were applied in 0.5, 1, and 2 multiples of IC50s determined for the primary MG1655 E. coli recipient. IC50 values for Carb, Cm, Kan, Ery, and Norf were as follows: 1.91, 1.92, 2.13, 20.20, and 0.05 g/ml (9). These growth conditions were chosen to restrict growth during conjugation. After 1 hour, cell mixtures were vortexed to disrupt conjugation, pelleted, and resuspended in 500 l of M9CA. The separated donor and recipient conjugation control aliquots were then mixed to track outgrowth conjugation.

The experimental and outgrowth conjugation control curves must be displaced in time; otherwise, OD will not reach target OD600 thresholds. For this reason, all cell mixtures were diluted 150 in M9CA with dual antibiotic selection [Carb (100 g/ml), Cm (70 g/ml), and Kan (50 g/ml)] according to the donor-recipient pairs and then distributed three times in 150-l volumes onto a microtiter plate. Microtiter cultures were covered with 50 l of mineral oil to prevent evaporation and grown in a plate reader for 24 hours at 37C, shaking before each OD600 measurement. The 150 dilution was chosen on the basis of an estimated of ~1014 from previous growth-restricted E. coli measurements. For best results, T0 should be maximized while minimizing outgrowth . Outgrowth dilutions and temperature may need to be adjusted on a strain-by-strain basis to optimize separation between experimental and control curves. For E. coli, the most common plasmids belong to the IncF family. Therefore, to maximize T0 with the E. coli library, we used rich, buffered TB media for optimal conjugative pili formation and exponential-phase donor cultures for activation of F plasmid transfer machinery (30). Conversely, recipients are kept in stationary phase for decreased motility or cell wall modifications thought to improve pili tip searching (9, 36).

Transconjugant growth curves were passed through a moving average filter in MATLAB to reduce noise. Time to specified OD600 threshold was found via linear interpolation. OD600 thresholds were typically chosen between 0.03 and 0.05 in early exponential phase to reduce background noise, maintain the cell density:OD relationship, and lessen postantibiotic effects (37). Within this range, changes in OD threshold had little effect on the correlation between and T0 (fig. S2B).

Transconjugant cultures were grown following the time to threshold protocol to accurately recreate postconjugation outgrowth conditions. Once resuspended in M9 media with Carb (100 g/ml) and Cm (70 g/ml), the cultures were serially diluted by 107 and plated on LB agar to determine T0 via colony-forming units (CFUs). These dilutions were then covered in 50 l of mineral oil and grown in a plate reader as before for 24 hours. With known T0, we constructed standard curves for each transconjugant strain by calculating from growth curves at varied OD thresholds. We find that defined M9 with Carb (100 g/ml) and Cm (70 g/ml) antibiotic concentrations minimizes standard curve variation across strains.

Time to threshold results () were normalized by subtracting from the no-antibiotic control yielding a value. An outlier for both ESBL41 and ESBL168 was removed due to unambiguous plate reader and experimental error, respectively, to preserve data integrity. Triplicate measures were parsed with ANOVA in R to reveal significant global interactions among strain, antibiotic, and concentration variables. Tukey post hoc test was performed for significant interactions. All tests are two tailed, and all replicates are technical unless indicated otherwise.

We selected 19 strains for whole-genome sequencing covering a range of conjugation dynamics. Genomic DNA was extracted using the QIAGEN MagAttract highmolecular weight DNA kit (catalog ID: 67563) from cultures grown for 16 hours until a density of approximately 109 cells/ml. DNA libraries were prepared according to PacBios recommendations and sequenced using the PacBio Sequel system.

All samples were assembled and polished using the PacBio SMRT Analysis assembly pipeline (SMRTLink version 5.1.0.26412), which uses HGAP 4 for assembly and Quiver for assembly polishing. Default parameters were applied, with the following exceptions: genome length was set to 5 Mb, the aggressive option was set to true, no read quality filters were applied, and the default falcon configuration parameters were supplanted with the following parameters: pa_DBsplit_option = -x500 -s200; ovlp_DBsplit_option = -x500 -s200. For samples with initial suboptimal assemblies, seed coverage was modified to increase the proportion of corrected reads. Seed coverage was set to 60 for ESBI168, GNO2448, and GNO4540, and 35 for GNO2766.

For constructing the phylogenetic tree, single-nucleotide polymorphisms (SNPs) were identified from genome assemblies (BioProject accession nos. PRJNA290784 and PRJNA551684) following the North Arizona SNP Pipeline (NASP) pipeline (38) using E. coli strain EC958 (GenBank accession no. HG941718.1) as a reference. Duplicated regions of the reference genome, including repeat regions and multiple gene copies, were determined by aligning the reference sequence to itself using the NUCmer-3.23 (39). SNPs that fell within these duplicate regions were excluded from further analysis to avoid false SNP calls due to ambiguous read alignment. Each query genome assembly was aligned to the reference with NUCmer-3.23. The best SNPs in all genomes compared to the reference were concatenated in a matrix. Phylogenetic trees were inferred using the maximum likelihood (ML) method available in RAxML (40, 41). This returned the best-found tree from 100 replicates inferred using the general time-reversible substitution model.

For Inc typing, the plasmid sequences were queried against a locally downloaded version (retrieved 22 May 2018) of the PlasmidFinder database (http://www.genomicepidemiology.org), using the recommended percentage coverage threshold of 60% and a more stringent percentage identity and e-value thresholds of 90% and 0.00001, respectively (42). MOB typing was performed as previously described, and default value was chosen for all parameters (43). Specifically, the e-value threshold of each MOB type was chosen as follows: MOBC, 0.001; MOBF, 0.01; MOBH, 0.01; MOBP, 1; MOBQ, 0.0001; and MOBV, 0.01. In addition, 247,882 protein sequences were extracted from a National Center for Biotechnology Information dataset of 6952 complete Enterobacteriaceae plasmids (44) and were compiled into a database in combination with the sequences of 2423 antibiotic resistance proteins from ResFinder database (retrieved 22 May 2018) (http://www.genomicepidemiology.org) (45) as predicted by prodigal v2.6.3 (46). Genome assemblies were further annotated using Prokka v1.13 (47) against the above compiled protein database. For comparison, plasmids were aligned to one another via BRIG, displaying sequence matches with nucleotide identity 70% (48).

Transconjugant conjugation was performed similarly to the time to threshold protocol with a few exceptions. Transconjugant donors were grown with shaking as DA28102 displays poor growth otherwise and fAYC002 was the sole recipient used. Donor, recipient, and second-generation transconjugant cell densities were quantified through LB agar plating and CFU counting.

Acknowledgments: We thank D. Anderson for contributing clinical isolates. We also thank the Duke Center for Genomic and Computational Biology, Duke Sequencing core facility, Duke Bioinformatics core facility, and J. Modliszewski, N. Devos, and G. Alexander Jr. specifically for their support with whole-genome sequencing of the isolates. Funding: L.Y. acknowledges support from the NIH (R01GM098642 and R01AI125604), Army Research Office (W911NF-14-1-0490), and the David and Lucile Packard Foundation. J.H.B. acknowledges a graduate fellowship from the NSFs IBIEM Training Grant. Author contributions: J.H.B. designed and performed the modeling and experimental analyses, interpreted the results, and wrote the manuscript. A.D. developed the analysis pipeline for time to threshold measurements and assisted with conjugation experiments. L.C., W.S., and M.X. processed, annotated, and analyzed the whole-genome sequencing results. A.J.L. conceived the research and assisted with the manuscript revisions. J.T.T. and V.G.F.J. provided clinical isolates and assisted with manuscript revisions. L.Y. conceived the research and assisted with the modeling, experimental design, data analyses, and manuscript revisions. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Genomic sequence data are available from GenBank with BioProject accession no. PRJNA551684. Additional data related to this paper may be requested from the authors.

Read the original:
Environmental and genetic determinants of plasmid mobility in pathogenic Escherichia coli - Science Advances

Read More...

America’s most widely consumed cooking oil causes genetic changes in the brain – University of California

Sunday, January 26th, 2020

New UC Riverside research shows soybean oil not only leads to obesity and diabetes, but could also affect neurological conditions like autism, Alzheimers disease, anxiety, and depression.

Used for fast food frying, added to packaged foods, and fed to livestock, soybean oil is by far the most widely produced and consumed edible oil in the U.S., according to the U.S. Department of Agriculture. In all likelihood, it is not healthy for humans.

It certainly is not good for mice. The new study, published this month in the journal Endocrinology, compared mice fed three different diets high in fat: soybean oil, soybean oil modified to be low in linoleic acid, and coconut oil.

The same UC Riverside research team found in 2015 that soybean oil induces obesity, diabetes, insulin resistance, and fatty liver in mice. Then in a 2017 study, the same group learned that if soybean oil is engineered to be low in linoleic acid, it induces less obesity and insulin resistance.

However, in the study released this month, researchers did not find any difference between the modified and unmodified soybean oils effects on the brain. Specifically, the scientists found pronounced effects of the oil on the hypothalamus, where a number of critical processes take place.

The hypothalamus regulates body weight via your metabolism, maintains body temperature, is critical for reproduction and physical growth as well as your response to stress, said Margarita Curras-Collazo, a UC Riversideassociate professor of neuroscience and lead author on the study.

The team determined a number of genes in mice fed soybean oil were not functioning correctly. One such gene produces the love hormone, oxytocin. In soybean oil-fed mice, levels of oxytocin in the hypothalamus went down.

The research team discovered roughly 100 other genes also affected by the soybean oil diet. They believe this discovery could have ramifications not just for energy metabolism, but also for proper brain function and diseases such as autism or Parkinsons disease. However, it is important to note there is no proof the oil causes these diseases.

Additionally, the team notes the findings only apply to soybean oil not to other soy products or to other vegetable oils.

Do not throw out your tofu, soymilk, edamame, or soy sauce, said Frances Sladek, a UC Riverside toxicologist and professor of cell biology. Many soy products only contain small amounts of the oil, and large amounts of healthful compounds such as essential fatty acids and proteins.

A caveat for readers concerned about their most recent meal is that this study was conducted on mice, and mouse studies do not always translate to the same results in humans.

Also, this study utilized male mice. Because oxytocin is so important for maternal health and promotes mother-child bonding, similar studies need to be performed using female mice.

One additional note on this study the research team has not yet isolated which chemicals in the oil are responsible for the changes they found in the hypothalamus. But they have ruled out two candidates. It is not linoleic acid, since the modified oil also produced genetic disruptions; nor is it stigmasterol, a cholesterol-like chemical found naturally in soybean oil.

Identifying the compounds responsible for the negative effects is an important area for the teams future research.

This could help design healthier dietary oils in the future, said Poonamjot Deol, an assistant project scientist in Sladeks laboratory and first author on the study.

The dogma is that saturated fat is bad and unsaturated fat is good. Soybean oil is a polyunsaturated fat, but the idea that its good for you is just not proven, Sladek said.

Indeed, coconut oil, which contains saturated fats, produced very few changes in the hypothalamic genes.

If theres one message I want people to take away, its this: reduce consumption of soybean oil, Deol said about the most recent study.

Go here to read the rest:
America's most widely consumed cooking oil causes genetic changes in the brain - University of California

Read More...

Ice hockey: Belfast Giants give boy with genetic disorder ‘reason to fight’ – BBC News

Sunday, January 26th, 2020

Media playback is unsupported on your device

"Is my blood teal?"

It may sound like a surprising question for a doctor to hear - but this isn't just any patient. This is Blake McCaughey, a Belfast Giants superfan.

The 12-year-old, from Tandragee in County Armagh, has a rare genetic disorder that means he will spend the foreseeable future in hospital, hooked up to pumps, for up to 20 hours a day.

But ice hockey has become "the reason he fights so hard through all these challenges".

He spends hours every day watching the sport from his hospital bed, which has been brightened up with teal pillows, in support of his beloved team.

When player Spiro Goulakos broke his ice hockey stick, it was used to make Blake a new pair of crutches.

"For Blake, life is hockey - everything that drives him through rough times will be about hockey and the Giants," his mum, Christine, told BBC News NI.

Blake was born with two chromosome deletions and abnormal muscle fibres.

By the time he was 16 months old, he had had 33 hospital admissions and battled pneumonia 19 times. Since then, he has been designated "nil by mouth".

In May 2017, he had open-heart surgery.

"When he was coming round from surgery, one of the Belfast Giants was there, holding his hand," said Christine.

Blake recovered well but, two years later, his health declined: His gut and bowel stopped absorbing nutrients and his heart rate, blood pressure and body temperature dangerously lowered.

Just last week he had more surgery to help with feeding and he will remain in hospital until he has gained weight.

"When Blake has a bad day, a simple photo or video call from one of his hockey buddies helps him keep fighting," said Christine.

"The Giants have always been a rock to Blake and us, and Blake has no bones in saying that Belfast Giants head coach Adam Keefe is his best mate, although he doesn't like Adam getting cross on game nights on the bench."

When Blake is well enough to leave the hospital, watching ice hockey is always at the top of his to-do list. It's even better when he gets to go with his little sister Pixie.

"He hates to miss a game," said Christine.

"Unlike most 12 year olds, Blake will never get to experience playing hockey but, with friends like the Belfast Giants, they make the impossible very possible and on a few occasions have had Blake out of his wheelchair, pull on the skates and be held whilst he skates in the SSE Arena."

His love for ice hockey has even caught the attention of other teams in the Elite Ice Hockey League (EIHL), the UK's premier competition, who send him videos and messages of love and support.

"Social media has brought us many friends on our journey from far and wide, and especially the hockey community," said Christine.

"Every team in the EIHL has looked after Blake so well and he's got good friends on every team. They have all reached out when Blake has needed a little encouragement along the way.

"Players for the Giants come and go, depending on their contracts, but some of our closest friends have been found through the Giants and no matter where they are in the world, they still keep very much in touch," she added.

"We use social media to spread awareness of Blake's condition and to share his amazing attitude to life, the strength and courage he has pulls us all through. His personality is one of a kind.

"When you meet him for the first time, you will see a shy little boy in a wheelchair but he's an absolute character and fond of the girls, especially nurses and doctors!

"He is a mischievous, fun-loving, hockey-crazed boy who spends hours watching hockey, talking hockey and even sleeps in hockey bedding.

"Blake loves everything teal and they are the reason he fights so hard through all these challenges."

Go here to read the rest:
Ice hockey: Belfast Giants give boy with genetic disorder 'reason to fight' - BBC News

Read More...

GyanSys Selected by AgReliant Genetics as the Primary Partner for Their Implementation of SAP S/4HANA as Part of Their Digital Transformation -…

Sunday, January 26th, 2020

CARMEL, Ind., Jan. 24, 2020 /PRNewswire/ --AgReliant Genetics, a leader in seed research, production and provider of seed solutions, signed a contract with GyanSys Inc. ("GyanSys"), a leading IT services provider headquartered in Indiana, to implementSAP S/4HANA on HANA Enterprise Cloud (HEC) as part of their digital transformation journey to replace their legacy ERP systems.

Steve Thompson, CIO of AgReliant Genetics "GyanSys led our team to conduct S/4HANA Best Practice workshops, gap analysis, and recommended the right SAP software bill-of-materials. AgReliant is excited to start our digital transformation journey partnering with GyanSys to build a scalable digital core for our Finance, Purchasing, Planning, Sales, Manufacturing, and Warehouse Management systems."

Rajkishore Una, President & CEO of GyanSys "GyanSys is committed to successfully deliver AgReliant Genetics' new SAP environment with our global delivery approach and our best practice-led implementation methodology. We are bringing our expertise in SAP S/4HANA digital core, alongside BPC, EWM, aATP, Manufacturing for Planning & Scheduling, and Analytics Cloud, for AgReliant to derive the most value from this strategic investment."

About AgReliant Genetics:

AgReliant Genetics offers corn, soybean, sorghum, and alfalfa seed solutions to farmers through their product brands. Contact your local AgriGold, LG Seeds, or PRIDE Seeds representative for more information.

Learn more about AgReliant Geneticsat http://www.agreliantgenetics.com.

About GyanSys Inc.:

GyanSys is a mid-tier global systems integrator specializing in SAP, Salesforce, Microsoft, and ServiceNow Platforms to improve the Sales, Finance, Supply Chain, Manufacturing, Operations, and HR business processes to support digital transformation.

Headquartered in Indiana, GyanSys was founded in 2005 and has approximately 1,000+ professionals globally serving 125+ customers across various industries, including the manufacturing, automotive, high-tech, CPG, and life sciences industries.

For more information about GyanSys, visit http://www.gyansys.com.

For press inquiries and more information, contact:Cliff SaitoDigital Marketing ManagerE-mail: cliff.saito@gyansys.com

Related Images

gyansys-logo.png GyanSys Logo

Related Links

AgReliant Genetics Website

GyanSys Website

SOURCE GyanSys

Home

See the original post:
GyanSys Selected by AgReliant Genetics as the Primary Partner for Their Implementation of SAP S/4HANA as Part of Their Digital Transformation -...

Read More...

Genetic Non-Discrimination Bill Advances in Florida – The National Law Review

Sunday, January 26th, 2020

Thursday, January 23, 2020

Florida could be the first state to deny life and long-term care insurers access to genetic test results. Under a new bill titled Genetic Information for Insurance Purposes (HB 1189), life insurers and long-term care insurers are prohibited from canceling, limiting, or denying coverage, or establishing differentials in premium rates based on genetic information. In addition, HB 1189 would prevent life insurers and long-term care insurers from requiring or soliciting genetic information, using genetic test results, or considering a person's decisions or actions relating to genetic testing in any manner for any insurance purposes.

On Jan. 16, the Florida House Health & Human Services Committee passed HB 1189 without any debate. The bill is now being reviewed by the Commerce Committee, which will have to clear the bill before it would be ready to go to the full House.

HB 1189 is sponsored by Representative Chris Sprowls, the incoming Speaker-designate. It is the only bill he has filed this year. In the Senate, the bill is sponsored by Kelli Stargel, who is part of Senate leadership. Given HB 1189s sponsors, the issue will likely be a high profile one, and will have a good chance of passing in the next year or two.

Existing federal law, the Genetic Information Nondiscrimination Act (GINA), protects Americans from discrimination in health insurance, employment decisions, and employee benefit decisions on the basis of genetic information. Under GINA, U.S. insurance companies and health plans (including both group and individual insurers, as well as federally regulated plans) are prohibited from:

looking at predictive genetic information or genetic services before enrollment;

requesting or requiring that individuals or their family members take a genetic test;

restricting enrollment based on genetic information;

changing premiums based on genetic information.

GINA, however, does not cover life, long-term care, or disability insurance providers. As a result, those companies can ask about health, family history of disease, or genetic information, and reject those that are deemed too risky.

2020 Greenberg Traurig, LLP. All rights reserved.

The rest is here:
Genetic Non-Discrimination Bill Advances in Florida - The National Law Review

Read More...

Genetic test developed to predict onset of glaucoma – The Siasat Daily

Sunday, January 26th, 2020

Washington: A group of researchers from Australia has formulated a genetic test that could detect peoples susceptibility towards developing glaucoma, which is a debilitating ocular disease that can potentially make its sufferers go blind.

The team of scientists suggests that there are 107 genes that are responsible for the onset of this condition.

They are looking forward to 20,000 peoples participation in their Genetics of Glaucoma Study in order to help them find more genes involved in the disease.

Glaucoma is characterised by progressive damage and degeneration of the optic nerve which also causes gradual loss of vision. It is the leading cause of irreversible blindness worldwide and is predicted to affect 76 million people by 2020.

There is still no proven cure for the disease, but treatment can reliably slow or halt deterioration in most cases. Up to 50 percent of those affected are not even aware.

Stuart MacGregor, lead researcher and the head of QIMR Berghofers Statistical Genetics Group, Associate Professor, said that identifying new genes allowed them to develop a glaucoma polygenic risk score (PRS) that can predict who is likely to get the eye disease.

Glaucoma is a genetic disease and the best way to prevent the loss of sight from glaucoma is through early detection and treatment, MacGregor defined.

Our study found that by analysing DNA collected from saliva or blood, we could determine how likely a person was to develop the disease and who should be offered early treatment and/or monitoring, he added.

He also feels that unlike existing eye health checks that are based on eye pressure or optic nerve damage, the genetic test can be done before damage begins so that regular screening can be put in place.

Clinical lead researcher and academic head of the Department of Ophthalmology at Flinders University, Professor Jamie Craig, said that the study results gave hope that mass screening for glaucoma could be offered in the future.

There are Australians who, if theyd had appropriate treatment a few years earlier, wouldnt have gone blind, said Professor Craig, who is also a consultant ophthalmologist.

One in 30 Australians has glaucoma, but most people only find out they have it when they go to the optometrist because they are losing vision, or for a general eye check, shares Craig, continuing, Early detection is paramount because existing treatments cant restore vision that has been lost, and late detection of glaucoma is a major risk factor for blindness.

He said that glaucoma can arise at any age but most of those affected are in their 50s or older, so their aim is to offer blood tests to people of that age to find out if they are at risk, and then hopefully act on it.

This test is likely to be helpful in identifying those who would benefit from a more aggressive intervention such as surgery rather than simple eyedrops.

The researchers are hoping to get in touch with people with a family history of the disease. We want to know who will get glaucoma, and for those who are susceptible, we want to be able to pinpoint at what age theyre going to get it, said Associate Professor MacGregor.

The researcher concluded, That would allow us to develop a personalised approach for earlier treatment of high-risk individuals, and means people at lower risk could have less intensive monitoring and treatment. This would have benefits for patients, doctors and the health care system with reduced interventions and reduced costs.

View original post here:
Genetic test developed to predict onset of glaucoma - The Siasat Daily

Read More...

‘Genetic mutations must be regulated’ – Telangana Today

Sunday, January 26th, 2020

Hyderabad: Creating super humans through genetic mutations is a red line that should not be crossed, said Prof. Virjinijus Siksnys, the biochemist who developed the gene-editing tool CRISPR, here on Friday.

CRISPR is a very powerful technology and people are now just testing boundaries of this technology. Scientists, in general, agree that you can use the gene-editing tool to correct mutations to cure diseases. But, improving humans is a Pandoras Box, which should be avoided, he said.

Prof Sriksnys, a biochemist from Institute of Biotechnology, Vilnius University, Lithuania, while delivering Dr Manohar VN Shirodkar Memorial Lecture of Telangana Academy of Sciences (TAS) at IICT, said there was a definite need for regulatory authorities from the US and European Union to come together and put in place a framework for the CRISPR technology.

Many discussions are ongoing on having regulations in the US and EU. Hopefully, in the coming few years, there will be some regulations in place. CRISPR is a tool that can be used for different applications and it depends on us on how we are going to use it, he said.

CRISPR enables geneticists to edit parts of the genome by removing and adding or altering sections of the DNA sequence. I believe such mutations can be introduced in plants very quickly. Usually, it takes a long time to develop better plant varieties. But, CRISPR technology can help speed up the process of generating better plant varieties, he said.

Senior office-bearers of TAS including its president Prof K Narasimha Reddy, former president Dr CH Mohan Rao, IICT Director S Chandrasekhar, CCMB Director RK Mishra and students from different schools were present.

Now you can get handpicked stories from Telangana Today on WhatsApp / Telegram everyday. Click these links to subscribe and save this number 9182563636 on your contacts.

Click to follow Telangana Today Facebook page and Twitter

Read more:
'Genetic mutations must be regulated' - Telangana Today

Read More...

Page 24«..1020..23242526..3040..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick